

NBER WORKING PAPER SERIES

OPTIMAL MANAGED COMPETITION SUBSIDIES

Keaton S. Miller  
Amil Petrin  
Robert Town  
Michael Chernew

Working Paper 25616  
<http://www.nber.org/papers/w25616>

NATIONAL BUREAU OF ECONOMIC RESEARCH  
1050 Massachusetts Avenue  
Cambridge, MA 02138  
February 2019

The authors would like to thank Mark Colas, Francesco Decarolis, Clare Evans, David Evans, Gautam Gowrisankaran, Ben Hansen, Kendall Houghton, Van Kolpin, Scott Petty, Jeremy Piger, Christopher Snyder, Glen Waddell, Wes Wilson, and seminar and conference participants at the University of Oregon, the University of Minnesota, the University of Texas-Austin, the 2019 NBER Winter IO and Insurance Meetings, the International Industrial Organization Conference, North American and European Meetings of the Econometric Society, and the Asian Workshop on Econometrics and Health Economics for helpful comments and feedback. All errors are our own. We are grateful for support from the National Institute on Aging under grant P01 AG032952. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.

NBER working papers are circulated for discussion and comment purposes. They have not been peer-reviewed or been subject to the review by the NBER Board of Directors that accompanies official NBER publications.

© 2019 by Keaton S. Miller, Amil Petrin, Robert Town, and Michael Chernew. All rights reserved. Short sections of text, not to exceed two paragraphs, may be quoted without explicit permission provided that full credit, including © notice, is given to the source.

Optimal Managed Competition Subsidies

Keaton S. Miller, Amil Petrin, Robert Town, and Michael Chernew

NBER Working Paper No. 25616

February 2019

JEL No. I11,L13,L51

**ABSTRACT**

When markets fail to provide socially optimal outcomes, governments often intervene through ‘managed competition’ where firms compete for per-consumer subsidies. Subsidies are generally set across geographies according to estimates of the cost of government provision, a method which may not be welfare-maximizing. We introduce a framework for determining the optimal subsidy schedule that features heterogeneity in consumer preferences and inertia, and firms with heterogeneous costs that can set prices and product characteristics in response to changes in the subsidy. We apply it to the Medicare Advantage program, which offers Medicare recipients private insurance that replaces Traditional Medicare. We calculate counterfactual equilibria as a function of the subsidies by estimating policy functions for product characteristics from the data and solving for Nash equilibria in prices. The optimal schedule increases consumer surplus by 30% over the current policy and is well-approximated with a linear rule using market-level observables.

Keaton S. Miller  
University of Oregon  
Department of Economics  
1285 University of Oregon  
Eugene, OR 97403-1285  
keatonm@uoregon.edu

Amil Petrin  
Department of Economics  
University of Minnesota  
4-101 Hanson Hall  
Minneapolis, MN 55455  
and NBER  
petrin@umn.edu

Robert Town  
Department of Economics  
The University of Texas at Austin  
2225 Speedway  
BRB 1.116, C3100  
Austin, TX 78712  
and NBER  
robert.town@austin.utexas.edu

Michael Chernew  
Harvard Medical School  
Dept. of Health Care Policy  
180 Longwood Avenue  
Boston, MA 02115  
and NBER  
chernew@hcp.med.harvard.edu

# 1 Introduction

When the private market’s provision of a good or service deviates from the socially optimal outcome, welfare may be improved through government intervention. Often times the obvious intervention is direct government provision of the good or service. However, there is a long-standing concern that government production programs can be inefficient, as government bureaucracies may lack sufficient incentives to efficiently design and deliver goods. This concern has led to the idea that governments can either regulate private firms or procure goods directly from those firms. These approaches also raise a host of strategic and informational issues that make efficient implementation challenging (Laffont and Tirole, 1993).

An alternative approach is for a government to provide subsidies to consumers who purchase the good from competing firms under the rationale that profit maximization motives and competitive market pressures will push firms to provide the optimal quantity, variety, and quality at a price nearing marginal cost. This “managed competition” approach is widely employed by the US government to provide health insurance (Gruber, 2017). For example, under the “Medicare Advantage” program (MA), Medicare beneficiaries can forgo the government-operated traditional Medicare (TM) benefit structure and enroll in one of many differentiated health plans offered by private firms. The firm assumes the financial and logistic responsibilities of the enrollee’s care and, in return, receives a risk-adjusted per-capita payment from the government, based on a county-specific “benchmark rate,” and premium payments from the enrollee. A similar system is used by Medicare Part D and the individual insurance marketplaces created under the Affordable Care Act. Elements of the managed competition approach also appear in education, where public, charter, and private primary and secondary schools compete on program offerings, education quality, and productive efficiency (Hoxby, 2000, Levin, 2002), as well as housing policy, where new construction is influenced by differences in tax credits across geographies (Baum-Snow and Marion, 2009).

Consider a government which seeks to maximize consumer surplus by allocating a fixed subsidy budget  $\bar{B}$  across  $M$  markets denoted by  $m$ . Under a managed competition framework, the government chooses a schedule of market-level purchase subsidies  $\{B_m\}$  (i.e. the benchmark rates). Let  $CS_m(B_m)$  be the consumer surplus and  $GovExp_m(B_m)$  be the government spending in market  $m$  as a function of the benchmark rate. The generic optimal subsidy problem is given by

$$\max_{\{B_m\}} \sum_{m=1}^M CS_m(B_m) \quad \text{s.t.} \quad \sum_{m=1}^M GovExp_m(B_m) = \bar{B} \quad (1)$$

The solution to this problem depends on the derivatives of the *CS* and *GovExp* functions, which in turn depend on the equilibrium interactions between firm and consumer behavior from which the *CS* and *GovExp* functions are derived. In particular, this behavior often varies across markets, and simple examples show that the optimal subsidy should also vary across markets as a function of the costs of the private firms, the willingness-to-pay of consumers, and the way in which competition leads firms to transform additional subsidy dollars into consumer surplus. In practice, however, the subsidy schedule is typically determined by measures of the *government's* cost of providing the service in different markets, which may vary substantially from private firms' costs and may be unrelated to demand conditions. For example, MA benchmark rates are set solely as a function of average risk-adjusted county-level TM costs.

In this paper, we develop an approach for determining the optimal subsidy level across many markets in managed competition settings conditional on a fixed government budget. In our setup, multiproduct firms choose equilibrium prices and product characteristics in response to the subsidy level set by the government and other competitive conditions.<sup>1</sup> Consumers have heterogeneous demographic characteristics and choose plans based on observable plan characteristics and unobservable plan-specific 'quality.' We take the mechanism that links a county-level subsidy to payments to firms as fixed and focus on differences across markets. To our knowledge, we are the first to study the optimal subsidy level in differentiated products environments in which firms can adjust both price and non-price characteristics in response to changes in the subsidy.

We apply our approach to the MA program. Using individual-level panel data on consumer demographics, option sets, and choices for the years 2008-2015, we provide descriptive evidence that the current policy is suboptimal and that firms respond to different benchmark rates through changes in both prices and plan designs. The panel nature of our data allows us to estimate switching costs, which are relevant due to the prevalence of narrow provider networks. Our demographic variables include a self-reported health status which allows us to flexibly capture demand behaviors which vary with health. We estimate the parameters of our model and find that MA plans are more valuable to those who have lower income, lower educational attainment, are younger, and are in better health. The average cost to switch between MA insurers is \$523, which is comparable to the average annual plan premium of \$509. Firm costs differ both within and across markets. Our estimates imply that in 2015, the MA program generated a total of \$5.94 billion in

---

<sup>1</sup>We do not explore the effect of the subsidy on entry and exit. While insurers and plans in our data do enter and exit, the median share captured by new entrants is 0.18%. Decarolis et al. (2015) make a similar argument.

consumer surplus and \$4.75 billion in variable profit with \$98 billion in payments to MA plans.

To find the optimal subsidy schedule, we must calculate outcomes under counterfactual subsidies for each market. The traditional approach to computing counterfactual equilibria, searching for a fixed-point in firms' best-response functions, is impractical due to the complexity of MA products – we capture nearly 50 product characteristics. Instead, we estimate policy functions for product characteristics from the data, use those estimated functions to predict characteristics under counterfactual benchmarks and then solve the firms' first-order conditions for prices taking those characteristics as given. We find that an across-the-board increase in benchmarks by \$1 increases government expenditures by \$16.2 million and increases consumer surplus by \$5.19 million – in other words, the average marginal pass-through rate is 32%, though this rate varies across markets.

We find the optimal policy is meaningfully different from the current policy – the average difference between the optimal benchmark and the 2015 benchmark is 3.6% or \$330. Our estimates imply that the optimal benchmarks increase average consumer surplus 30% from \$149 to \$193 per Medicare-beneficiary-year. Relative to the 2015 policy, the optimal policy creates winners and losers – consumer surplus in markets with larger benchmarks increases 62%, while the surplus in markets with smaller benchmarks decreases 25%. We show that the derivatives of the consumer surplus and government expenditure functions which drive the results are related to market-level observables, and that a linear rule based on these observables results in a 4.4% reduction in consumer surplus and a 0.5% increase in government expenditures relative to the optimal policy. We explore other social welfare functions and find benchmark schedules that increase the average consumer surplus and reduce the variance relative to the 2015 policy.

We build upon an extensive MA literature; see McGuire et al. (2011) for a review. Our work is most related to Town and Liu (2003), Lustig (2010), Aizawa and Kim (2018) and Curto et al. (2018). Town and Liu (2003) estimate a nested logit demand system for MA plans and calculate that the program generated \$113 in consumer surplus and \$244 in profits per Medicare beneficiary in 2000 with significant geographic variation. Curto et al. (2018) estimate a similar model using more recent data and find that the program generated approximately \$600 in total annual surplus, with the majority captured by insurers. They also estimate that average MA plan costs are 12% lower than TM costs, though in 47% of counties MA does not have a cost advantage over TM. Nosal (2012) estimates a dynamic demand model of MA plan choice and finds very large switching costs—\$4,000 at the median. Aizawa and Kim (2018) estimate a demand model that is similar to ours in order to explore the role of advertising in equilibrium selection. They analyze a counterfactual price

equilibrium when advertising is prohibited, but do not endogenize other product characteristics.

There is a literature examining the rate at which MA benchmark increases are passed through to consumer surplus. Using an unanticipated change in the benchmark in 2000, Cabral et al. (2018) estimate a passthrough rate of 54%, while Duggan et al. (2016) use variation in the benchmark across urban and rural counties and estimate a smaller passthrough. Song et al. (2013) calculate a passthrough from benchmarks to plan bids, which are a measure of premiums and the value of benefits, of 53%. We expand upon this literature by considering firms' choices of plan features, not just premiums, in response to benchmark changes. In this way, our work is related to Fan (2013).

We also relate to recent work on optimal subsidy structures in different health insurance contexts. Tebaldi (2017), Jaffe and Shepard (2017) and Einav et al. (2018) examine the optimality of different subsidy and/or risk-adjustment strategies in different ACA insurance exchanges. Ericson and Starc (2015) examine the implications of age-based price regulation in an ACA-like insurance exchange. Bundorf et al. (2012) study health-status-linked premiums in the employer-sponsored setting. More broadly, we relate to a literature that considers various strategies designed to address adverse selection—see Geruso and Layton (2017) for a review. MA subsidies are risk-adjusted, apparently successfully (Newhouse et al., 2015), and therefore we do not examine that issue here. In addition to exploring the effectiveness of the risk-adjustment system, Decarolis et al. (2015) examine the optimality of using vouchers versus the current subsidy strategy in Medicare Part D and find that the two systems generate similar welfare. None of these papers examine the impact of subsidies on non-premium plan characteristics.

We discuss the institutional details of the Medicare Advantage program in Section 2, and provide simple examples of the optimal subsidy problem in Section 3. We detail our data on Medicare beneficiaries and MA plans in Section 4. We present our full model in Section 5 and estimate its parameters in Section 6. Section 7 describes our approach to counterfactual analysis, and we present the results in Section 8. We conclude in Section 9.

## **2 The Medicare Advantage Program**

Medicare was enacted in 1965. In its original form, the program provided health care to seniors (age 65 or older) through its Part A (hospital) and Part B (physician and outpatient) insurance programs, respectively. Under its fee-for-service (FFS) structure, private providers treat beneficiaries and Medicare pays the provider according to a pre-set reimbursement schedule while beneficiaries pay

applicable copays and/or coinsurance. In 1972 eligibility was expanded to include those who are eligible for Social Security disability benefits and those with end-stage renal disease (ESRD).

Partly in response to the increasing costs of Medicare,<sup>2</sup> in 1982 Congress authorized Medicare administrators to engage in a series of “Part C” trials in which the government handed over management of the medical care of select groups of Medicare enrollees to private insurers in exchange for a payment that did not vary with the realized medical expenditures of each individual.<sup>3</sup> This program was brought to the entire country in the early 1990s under the name Medicare+Choice.

The Medicare+Choice program struggled to attract plans and nationwide enrollment hovered near 5 million – less than 10% of the Medicare population. Critics blamed low subsidy rates and the fact that flat payments incentivized firms to cream-skim relatively healthy individuals from the risk pool. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 aimed to remove this incentive by adding a comprehensive risk adjustment component to the payment mechanism. Under the new system, firms submit demographic and diagnostic data about enrollees to the Centers for Medicare and Medicaid Services (CMS) at the time of enrollment. CMS assigns each enrollee a score based on its FFS expenditures on similar individuals in Traditional Medicare (TM). Payments to firms are then adjusted according to these risk scores. Proponents argued that this mechanism would compensate firms for taking on risk without reimbursing specific procedures – thus maintaining the profit motive which would (in theory) lead to cost reductions. The program was renamed Medicare Advantage (MA). By 2015, 95% of Medicare beneficiaries had an MA plan in their county and enrollments had increased to 16.3 million.<sup>4</sup>

A beneficiary who enrolls in an MA plan forgoes TM benefits and receives medical benefits from the MA plan exclusively. MA enrollees pay the Medicare Part B premium and may pay a private plan premium as well. Firms compete along the dimensions of benefit design, premia, and provider networks, and often heavily market their plans (Aizawa and Kim, 2018). Firms also differ in their organization. Most plans are offered by health maintenance organizations (HMOs), though preferred provider organizations (PPOs) and private fee-for-service plans (PFFS) are also offered in many locations. These firm types differ in their method of service delivery: HMOs generally deliver care through providers who work directly for the firm, while PPOs form a network of independent providers. PFFS plans offer a flat reimbursement rate per procedure, and providers may choose on a case-by-case or service-by-service basis to accept patients. HMOs generally require recipients to

---

<sup>2</sup>In 1970, Medicare composed about 0.5% of GDP. By 1980, Medicare had grown to 1.1% of GDP.

<sup>3</sup>These trial contracts were based in part on the ideas of Enthoven (1978).

<sup>4</sup>See McGuire et al. (2011) for a comprehensive history of the Medicare Advantage program.

choose a primary care provider and obtain referrals to see specialists. PPOs may or may not require referrals. Both types often require increased cost-sharing for ‘out-of-network’ service providers. However, MA plans generally provide a more generous benefit package than TM, including benefit categories not included under TM, such as dental and eye coverage. Many plans include a drug benefit. Plans may also offer a reduction in the Part B premium.<sup>5</sup>

The enrollee-specific subsidy from CMS to insurers is based on a fixed “benchmark” rate for each county, which varies significantly across geographies and over time (Newhouse et al., 2012). CMS calculates the benchmark schedule each year by starting with the average risk-adjusted per-capita FFS Medicare spending within the county.<sup>6</sup> Counties are then ranked by average spending and placed into quartiles. The benchmark rate for counties in the top quartile of FFS spending is set to 95% of their average FFS spending. The benchmark rate for the second quartile is set to 100% of average FFS spending, the third quartile benchmark is 107.5% of average FFS spending, and the bottom quartile is set to 115% of average FFS spending. A cap and floor that varies by urban/rural status is applied to the benchmark rates.

Each year, after benchmarks are released, insurers submit plan-level ‘bids’ for particular counties. The bid for each plan represents the insurer’s offer to provide a stated set of benefits to a person of average risk for the next year in exchange for a particular price. The final bid amount must be related to the firm’s revenue requirements and may be above or below the benchmark rate. Firms who bid above the benchmark rate must charge premiums to enrollees. Firms who bid below the benchmark receive a portion of the difference as a ‘rebate’ that must be passed on to consumers through increased benefits or lower Medicare Part B premiums. MA plans that offer a prescription drug benefit submit a separate bid which maps in a similar way to a Part D premium.

At the beginning of our data, the rebate payment was equal to 75% of the difference between the bid and the benchmark. In 2008, CMS introduced a system to measure insurer quality by assessing performance along multiple dimensions and assigning a summary ‘star rating’ to firms. In 2012, after multiple iterations of the criteria, CMS began using the rating to determine the rebate for each plan. Under this new approach, firms with at least 4.5 stars (out of five) earn 70% of the difference between the benchmark and the bid. New entrants and those with 3.5 or 4 stars earn

---

<sup>5</sup>MA allows firms to register as ‘Regional PPOs’ if they cover all counties in a CMS-defined area – at minimum an entire state. Regional PPOs face a slightly different payment policy than that described in this section, though they set premiums and benefits similarly to other plans. For computational tractability, we assume Regional PPO plans operate identically to other plans in our counterfactual simulation. As Regional PPO plans have a total market share of 1.0% in our data, our results are not likely to be affected by this assumption.

<sup>6</sup>This average is formed by adding the average Part A spending to the average Part B spending (as opposed to the average sum of Part A and Part B spending).



65% of the difference. All others earn 50%. Additionally, firms with at least 4 stars have a 5% bonus applied to the benchmark rate itself (CMS Office of the Actuary, 2017).

Beneficiaries can enroll in plans during an “Open Enrollment” period in the fall prior to the plan year. Beneficiaries may also enroll in MA when they become newly Medicare eligible and after “major” life changes (e.g. relocation, death in the family, etc.).<sup>7</sup> After the enrollment period closes, firms collect and transmit risk-adjustment information to CMS, which calculates the final subsidies and begins monthly payments in January of the following year.

To summarize, the payment from CMS to insurers for an enrollee  $i$  living in county  $m$  enrolled in plan  $j$  in year  $t$  based on a benchmark  $B_{mt}$  can be calculated with

$$Payment_{ijt} = \begin{cases} B_{mt} \times \phi_{jt} \times RiskAdjustment_{it} & \text{if } bid_{jt} \geq B_{mt}\phi_{jt} \\ (bid_{jt} + \lambda_{jt} \times (B_{mt} \times \phi_{jt} - bid_{jt})) \times RiskAdjustment_{it} & \text{if } bid_{jt} < B_{mt}\phi_{jt} \end{cases} \quad (2)$$

where  $\phi_{jt}$  captures any bonus to the benchmark rate and  $\lambda_{jt}$  is the rebate percentage, which may vary with the rating. For simplicity, we denote the market-level (i.e. county-year level) benchmark with  $B_m$  and denote risk-neutral (i.e.  $RiskAdjustment = 1.0$ ) plan-specific payments with  $B_j$ .

MA is a significant component of the federal budget. In 2015, payments to plans in our data were \$98 billion – traditional Medicare spending on the individuals in our data totaled \$298 billion. MA is also relatively concentrated: the top four firms nationwide, United Health Group, Humana, Kaiser, and Aetna, have 56% of total enrollment. The average beneficiary has access to 10 plan options with 64% of beneficiaries having access to 5 or more plans. 25% of beneficiaries in our 2015 data have access to 3 or fewer plans. The average bid is 90% of TM costs (MedPAC, 2017).

Figure 1 illustrates the 2015 policy and the resulting market outcomes with county-level maps of the US. The top map illustrates the ratio of the 2015 benchmark rate to the average FFS spending in 2015. The bottom map illustrates the difference between the MA enrollment percentage in each county and the national average. As consumer surplus is related to the total MA share, these graphs offer a simple check of the current government policy. If private costs are tightly linked to the government’s costs, and differences in those costs were the only source of heterogeneity across markets, then we would expect those areas which had larger benchmarks (relative to FFS spending) to have greater enrollment (relative to the national average). Instead, we see a significant deviation from this pattern. Areas with high relative benchmarks, such as much of New Mexico,

---

<sup>7</sup>More recently, enrollees have been allowed to switch to a “5 star” plan at anytime during the year.

do not have particularly high enrollment. Furthermore, those areas with high enrollment, such as Minnesota and southwestern Pennsylvania, do not have particularly high relative benchmarks. We thus conclude that there may be gains by redistributing government funds across counties.<sup>8</sup>

### 3 Simple Examples of the Optimal Subsidy Problem

Before moving to the full model, we present simple examples of the optimal subsidy problem described in Equation 1 which illustrate the gains that can be obtained by considering the interactions between supply and demand conditions across markets over setting subsidies as a function of the government’s cost alone. We focus on a discrete choice demand framework under monopoly, a simplified version of the model of MA we will introduce in Section 5 to model MA.

In each market  $m$ , there exists a measure of consumers, denoted by  $i$ , and a single firm providing a single product at price  $p_m$ . Consumers choose either to buy the product offered by the firm or the outside option of government provision. The utility of purchasing the good from the monopolist is given by  $u_{im} = \alpha_m p_m + \beta_m + \epsilon_{im}$ . In this equation,  $\alpha_m$  is a market-specific price sensitivity,  $\beta_m$  is a market-specific taste for the private good, and  $\epsilon_{im}$  is an per-consumer idiosyncratic taste for the good. Let  $\epsilon_{im}$  be drawn from the Type-I extreme value distribution, and normalize the utility of the outside good to zero. The probability that a consumer in market  $m$  purchases the good, which we will refer to as the inside share of the good, is then given by  $s_m = \frac{\exp(\alpha_m p_m + \beta_m)}{1 + \exp(\alpha_m p_m + \beta_m)}$ . Each market hosts a different monopolist firm, which faces marginal costs  $c_m$  and chooses the price  $p_m$  knowing the consumer demand characteristics described above and the government policy  $B_m$ , which consists of a per-purchase payment. The firm’s profit-maximization problem is therefore given by  $\max_{p_m} (p_m - c_m + B_m) s_m(p_m)$ .


If the consumer does not choose the private good, the government provides the good at a cost of  $TM_m$ . Let  $s_m(B_m)$  be the inside share of the good at the profit-maximizing price under policy  $B_m$ . The government’s expenditures are  $GovExp_m(B_m) = s_m(B_m) * B_m + (1 - s_m(B_m)) * TM_m$  and the consumer surplus is  $CS_m(B_m) = \frac{1}{\alpha_m} \ln(1 + \exp(\alpha_m p_m^*(B_m) + \beta_m))$ . This “inclusive value” form of consumer surplus is the amount consumers in market  $m$  would be willing to pay before knowing their idiosyncratic taste to have the option to purchase the good (Small and Rosen, 1981).

Table 1 provides numeric solutions to Equation 1 for several combinations of markets. In each example, markets differ by parameters  $\{\alpha_m, \beta_m, TM_m, c_m\}$ . We apply the MA benchmark policy

---

<sup>8</sup>Appendix Figures C.1 and C.2 present other views of the benchmark distribution.

**Figure 1: 2015 Medicare Advantage Benchmarks Relative to FFS Spending, and Relative Market Penetration, by County**



Notes: Data from CMS benchmark and enrollment files. The top map illustrates the ratio of the 2015 benchmark rate to the 2015 risk-adjusted FFS spending in each county. To show detail, the data are winsorized at the 5th and 95th percentiles. The bottom graph shows the difference between the Medicare Advantage penetration rate in each county and the overall penetration. Penetration is defined as the total number of people enrolled in any MA plan divided by the number of people eligible for Medicare benefits. Positive numbers, therefore, indicate that the county had a higher percentage of Medicare eligibles enrolled in an MA plan than the national average.

described in Section 2 to obtain an initial subsidy schedule  $B_m^{MA}$ . We calculate the government’s budget constraint under the MA policy and then solve for the optimal schedule holding the total budget fixed. We compare the per-market benchmark rate, government expenditures, and consumer surplus under the MA approach to the optimal approach. Across examples, the second market is identical and has “average” characteristics taken across the other markets.

In Example (a) the market with the lowest  $TM_m$  has still lower  $c_m$  and price sensitivity is higher when costs are lower. The optimal policy takes advantage of the cost savings available in the lowest-cost market and redistributes expenditures to the other two markets. The total consumer surplus increases by 14.6%.

Example (b) changes the relationship between firm costs and the government’s costs – while firm costs are still positively correlated with the government’s costs, firm costs are less extreme. In this example, the optimal policy moves more money in percentage terms from the lowest-cost market to pay for increases in the other two. The change in firm costs leads to a difference in the rank order of market outcomes: while in Example (a) the lowest-cost market has the highest consumer surplus, in Example (b) the highest-cost market has the highest consumer surplus. The optimal policy changes the rank order of consumer surplus across markets and increases the total by 16%. Example (c) duplicates the cost structure of Example (b) but reverses the relationship between price sensitivity and costs. This change results in the highest changes in government expenditures in percentage terms, as well as the largest increase (20.4%) in total consumer surplus.

Taken together, these examples illustrate important features of the optimal policy problem. First, there is a disconnect between the benchmark rate and the realized government expenditures and consumer surplus. Indeed, in Example (c) the optimal policy increases the benchmark rate and government spending by the greatest percentage in the third market, yet consumer surplus improves the most in percentage terms in the second market. As a corollary, the optimal policy depends not only on the interactions between supply and demand conditions in any particular market, but on the heterogeneity in those conditions across markets. While the second market is identical across all three examples, the optimal benchmark rate and corresponding expenditures and consumer surplus differ. Finally, all three examples illustrate significant improvements in consumer surplus over the MA policy, despite differences in the relationship between firm costs and the government’s costs.

**Table 1: Example solutions to simple optimal subsidy problems**

$\alpha_m$	$\beta_m$	$TM_m$	$c_m$	$B_m$			$GovExp_m$			$CS_m$			
				MA	Opt.	$\Delta\%$	MA	Opt.	$\Delta\%$	MA	Opt.	$\Delta\%$	
<i>(a): Firm costs are positively correlated with the government's cost</i>													
-3	-1	10	8	11.5	11.12	-3.34	11.30	10.95	-3.15	.677	.630	-6.87	
-2.5	0	12.5	12.5	12.5	13.11	4.84	12.50	12.76	2.11	.098	.229	133	
-2	1	15	18	14.25	16.63	16.7	15.00	15.09	.618	.000	.029	10,500	
										Total:	.775	.888	14.6
<i>(b): Firm costs are less positively correlated with the government's cost</i>													
-3	-1	10	11	11.5	10.85	-5.65	10.43	10.06	-3.54	.113	.026	-77.4	
-2.5	0	12.5	12.5	12.5	12.87	2.95	12.50	12.63	1.03	.098	.172	75.5	
-2	1	15	13.5	14.25	14.73	3.33	14.58	14.82	1.65	.409	.522	27.7	
										Total:	.620	.720	16
<i>(c): Price sensitivity is higher when costs are higher</i>													
-2	1	10	11	11.5	10.77	-6.36	10.75	10.23	-4.88	.347	.174	-49.9	
-2.5	0	12.5	12.5	12.5	13.05	4.42	12.50	12.73	1.84	.098	.216	120	
-3	-1	15	13.5	14.25	14.99	5.21	14.70	15.00	2.00	.169	.350	107	
										Total:	.614	.740	20.4

Notes: This table illustrates the solution to Equation 1 for sets of markets under the monopoly environment described in Section 3.  $\alpha_m, \beta_m, TM_m$ , and  $c_m$  are the market-level price sensitivity, taste for the good, government's marginal cost, and the monopolist's marginal cost, respectively.  $B_m$  is the benchmark rate set by the government, and  $CS_m$  and  $GovExp_m$  are the consumer surplus and government expenditures in each market. In each example, we calculate  $B_m$  using the MA policy described in Section 2 and use the total government expenditures as the budget constraint for Equation 1.  $\Delta\%$  denotes the percentage change in the outcome from the MA policy to the optimal policy.

## 4 Data

We combine administrative data on plan characteristics and enrollment from CMS with micro-level data on consumer choices from the Medicare Current Beneficiary Survey.

### 4.1 Medicare Advantage plans

Each year, CMS operates a Plan Finder website which allows consumers to compare the benefits of plans offered in their location. We obtain the Plan Finder database from CMS for the years 2008 to 2015. We extract plan premiums, the Part B premium reduction (if any), copays and coinsurance rates for primary care, specialist, and hospital visits, indicators for HMO, PPO, and PFFS plan types, and indicators for vision, dental, and prescription drug coverage of any kind for each plan-year. We also extract the county-level geographic coverage for each plan. We collect star ratings, plan-level bids,<sup>9</sup> and county-level benchmarks from other CMS sources. Finally, CMS releases

<sup>9</sup>We do not observe the bids directly. Rather, we observe plan-level risk-adjusted payments, including the rebate payment, county-level enrollments and benchmark rates. Combined with the payment rules described in Equation 2 and CMS rules for bids which cover multiple counties, we uniquely identify a bid for each plan-county.

enrollment counts each month for each county and plan. We average these monthly data over each plan year and combine them with CMS counts of the number of people eligible for Medicare benefits and not also eligible for Medicaid to form product shares at the plan-county-year level.

As part of the bidding and enrollment process, CMS calculates and publicizes out-of-pocket cost (OOPC) estimates for each plan. CMS creates these estimates by forming a representative bundle of services used by TM enrollees in different demographic groups. CMS then calculates the out-of-pocket costs for that bundle under each plan’s benefit structure, which implicitly assumes that service-level consumption patterns do not change between TM and MA. We collect the OOPC estimate for each plan by age group (Under 65, 65-69, 70-74, 75-79, 80-84, and Over 85) and health status (Excellent, Very Good, Good, Fair, and Poor).

We focus on the market for individual insurance described in Section 2, and drop plans sponsored by employers and plans designed for individuals who are “dual-eligible” for Medicare and Medicaid, as plans in these categories operate under a different payment system and benefit structure. Due to CMS data restrictions, we drop plan-county observations with ten or fewer enrollees.<sup>10</sup> For consistent presentation, we report statistics for plans which fall within our micro-data sample area.

Table 2 presents the mean characteristics of our 50,593 plan-county-year observations separated by benchmark quartiles calculated at the market (county-year) level. In the cross section, as benchmarks increase observable plan benefits generally improve.<sup>11</sup> The mean premium is \$607 in the first quartile, and \$443 in the fourth. Dental coverage is included in 55% of plans in the lowest quartile, and 69% of plans in the highest. Estimated out-of-pocket costs for a 75-79 year-old in good health vary from \$2,715 in the first quartile to \$2,336 in the fourth. These differences in benefits are correlated with differences in enrollment: average enrollment increases from 269 in the first quartile to 1,039 in the fourth. The total market-level MA share increases from .149 to .259.

These patterns are not always monotonic: the average deductible decreases from \$97.40 in the first quartile to \$87.30 in the second quartile before increasing to \$102.39 in the third quartile. These patterns reflect the fact that benchmarks are assigned to markets non-randomly as a function of average TM costs in previous years. Though the costs faced by private firms are likely different than average TM costs, they are certainly correlated and therefore the benchmark alone is an insufficient statistic for understanding the behavior of firms.

---

<sup>10</sup>CMS sources report that these observations are largely transient and created by individuals who move outside of their plan’s service area.

<sup>11</sup>Appendix Table C.1 presents unweighted and enrollment-weighted means across all observations. Appendix Table C.2 uses the panel nature of our data and reports the correlation between year-over-year changes in the benchmark and changes in same-plan product characteristics.

There are a number of potential explanations for this behavior. Traditionally, insurers are thought to choose prices and plan features in response to the risk of adverse selection (Rothschild and Stiglitz, 1976, Glazer and McGuire, 2000). A change in the benchmark rate could be seen as a signal of a change in the risk distribution of consumers in the market, which could lead plans to try to cream-skim by changing their product characteristics (Decarolis and Guglielmo, 2017) though related work has found that the current implementation of the risk-adjustment system effectively reduces incentives to cream-skim for cost reasons (Newhouse et al., 2015). Firms who engage in diagnostic practices which result in larger risk-adjustment payments may set product characteristics to encourage positive selection relative to opportunities to “upcode” (Geruso and Layton, 2018). Alternatively, the menu of copays, coinsurance rates, and other product features may not be fully salient to consumers (Curto et al., 2018). Finally, changes in the benchmark rate could result in different insurer-provider bargaining outcomes (Ho and Lee, 2018), which in turn would affect the marginal cost of specific services. We do not speculate about which of these mechanisms drives the firm response, but simply note that all may lead a firm to choose product characteristics in part as a function of the benchmark rate.

## 4.2 Medicare beneficiaries

Our individual-level data on Medicare beneficiaries come from the Medicare Current Beneficiary Survey (MCBS), a rolling-panel survey of a nationally representative sample of beneficiaries sponsored by CMS and produced by Westat. Participants are interviewed multiple times per year over three years, and responses are linked to CMS administrative and claims data to ensure accuracy.

We obtain the MCBS responses for 2008-2015.<sup>12</sup> We observe detailed demographic information, including income, age, sex, race, and education. Respondents self-report their health status, choosing between Excellent, Very Good, Good, Fair, and Poor. We transform these variables into indicators for each demographic group that match the groups captured by the plan-level OOPC estimates. We also observe the respondent’s county of residence and their MA plan, if any.<sup>13</sup>

The MCBS samples beneficiaries using a multi-level clustered procedure. First, several focus geographies consisting of metropolitan statistical areas or groups of contiguous nonmetropolitan counties are chosen randomly to reflect the diversity of urban and rural populations across the

---

<sup>12</sup>The MCBS did not release data for 2014.

<sup>13</sup>In some years, the MCBS does not report the plan choice directly and instead reports which firm the individual has chosen, along with information about plan features and any premiums paid by the individual. We match this data to the plan data to identify each individual’s choice.

**Table 2: Mean plan characteristics by market-level benchmark quartile**

Variable	Benchmark quartile			
	1st	2st	3rd	4th
Annual premium (\$)	607	545	512	443
Annual Part B premium reduction (\$)	8.01	21.45	31.79	43.83
Deductible (\$)	97.40	87.30	102.39	89.79
Out-of-pocket limit (\$)	4,334	4,208	3,446	3,766
Star rating	2.42	2.15	2.31	2.64
Supplemental coverage indicators				
Prescription drug	.735	.745	.749	.801
Dental	.554	.565	.571	.691
Vision	.852	.884	.869	.929
Plan type indicators				
HMO	.249	.394	.403	.610
PPO	.364	.298	.282	.221
PFFS	.387	.307	.315	.168
Copays				
Primary care (\$)	13.25	11.47	12.23	9.62
Specialist (\$)	31.39	28.48	28.68	25.15
Hospital stay (\$)	277	244	249	204.73
Coinsurance				
Primary care (%)	.658	.797	.388	.264
Specialist (%)	.417	.417	.411	.246
Hospital stay (%)	.057	.091	.062	.033
Selected CMS-estimated out-of-pocket costs				
65-69 year-old, excellent health (\$)	1,549	1,452	1,313	1,336
75-79 year-old, good health (\$)	2,715	2,612	2,339	2,336
85+ year-old, poor health (\$)	4,699	4,324	3,799	3,977
Annual benchmark (\$)	8,860	9,543	9,820	11,035
Plan-level enrollment	269	550	535	1,039
Market-level MA share	.149	.211	.235	.259
Observations	6,697	11,658	15,268	16,970

Notes: An observation is a county-year-plan; all reported figures are unweighted means across observations in the relevant quartile. The benchmark quartile is defined at the market (county-year) level. All dollar amounts are in 2015 dollars. The star rating is calculated by CMS and ranges from zero to five. We obtain 30 out-of-pocket cost estimates for each plan (five health status groups times six age ranges) though report only three here for brevity.



United States. Within each focus area, beneficiaries are chosen at random to be representative of the Medicare population as a whole. This procedure ensures that, although we do not observe beneficiaries in every county in the country, within a geographic area there is considerable variation in demographics and plan enrollment. The MCBS provides sampling weights which we use throughout our analysis to transform our results into a nationally representative form.

To model our MCBS micro-data as draws from the process that generates our plan-level enrollment data, we exclude any individuals who were eligible for Medicaid during the year, and those with missing address information. After applying these exclusions, the sum of the sample weights in the MCBS data differs from the sum of eligibles nationwide in our CMS data by less than 1%.

There are individuals in the MCBS data who do not fall into the standard set of Medicare beneficiaries often studied in the literature: age 65-plus retirees without outside insurance (Curto et al., 2018). However, these individuals are eligible to purchase MA plans and are therefore included in CMS’ enrollment files. These include individuals with employer-provided insurance plans, those whose original Medicare eligibility was not age-related, those with ESRD, and those who are not full-year enrollees in Part A and Part B. As these individuals purchase MA plans, we cannot exclude them without violating our model of the data-generating process. We instead include them and create ‘administrative’ indicator variables to capture their behavior.

Those who do not enroll in MA have access to other insurance options, and variation in the price of those options may make MA plans more or less attractive. We focus on Medicare supplemental insurance (a.k.a. Medigap) which pays for care not covered by TM. For example, TM covers 80% of the cost of physician visits, and a Medigap plan may pay for the rest. The design of Medigap plans is standardized by CMS and indexed by letters: all “Plan A” policies across insurers offer the same benefits. For each person, we obtain the rate for Medigap Plan C offered by United Healthcare that year from Weiss Ratings. Plan C covers most of the coinsurance and deductibles that beneficiaries are responsible for under TM and is the most popular Medigap plan.<sup>14</sup>

Summary statistics on our 58,444 individual-year observations covering 2,947 county-year markets and 32,993 unique individuals are reported in Table 3. The first two columns report means and standard deviations across all observations. The mean age of individuals in our data is 73. Slightly more than half of our observations are of females. Over 90% of individuals are coded by CMS as White, with 7.9% Black and 1.0% Hispanic. Over 75% self-report “Good” or better health. 24%

---

<sup>14</sup>Massachusetts, Minnesota, and Wisconsin have alternative plan definitions; in those states we use the rate for the plan closest to Plan C. Additionally, United Healthcare did not offer plans in New York during our study period. For individuals in New York, we averaged the Plan C rates offered by all other insurers.

report having college degrees and 18% did not graduate high school. 33% receive some insurance from a current or previous employer, and 16% are Medicare-eligible for reasons other than turning 65. The second set of columns splits the data by MA enrollment. On average, MA enrollees have lower income, are less likely to be White, and have lower educational attainment. Individuals with employer-provided insurance or with ESRD are less likely to be enrolled in MA.

The third and final set of columns of Table 3 illustrates the panel nature of our data and focuses on panel observations for which the individual was enrolled in TM in the previous year – 23,278 observations total. We split the data into those who switched from TM to MA (4.3% of observations), and those who remained on TM. Those who switched are generally similar to the larger group of MA enrollees. Some differences are seen in health status – switchers from TM to MA are slightly healthier on average than the broader MA population.

## 5 A Model of Medicare Advantage

Our model of MA builds upon the example introduced in Section 3 and leverages the rich individual-level information in the MCBS and the detailed plan data from CMS. The demand side is inspired by Goolsbee and Petrin (2004) and captures heterogeneity along multiple dimensions. In this sense, our demand model is similar to that of Aizawa and Kim (2018) although we estimate parameters with a different approach. On the supply side, we model multi-product insurers as profit-maximizers that choose prices and product characteristics. We take the number of firms and products as given.

Each period  $t$  begins with the government choosing benchmarks  $B_m$  for each market  $m$  (defined as a county) and Medigap insurers determining a price schedule  $\{p_0\}_m$ .  $B_m$  maps to plan-specific subsidies  $B_j$  via Equation 2 – the parameters  $\phi$  and  $\lambda$  are taken to be exogenous. Firms  $f \in \mathcal{F}_{mt}$  publicly observe costs and then simultaneously choose for each of their plans  $j \in \mathcal{J}_f$  product characteristics  $\{X, oopc, \xi\}_j$  and prices  $p_j$ . Consumers, denoted by  $i$ , then choose a single plan or the outside option of TM.

### 5.1 Demand

Consumers have demographic characteristics  $z_i$  which include income bracket  $g$  and age-and-health-status type  $h$ . Let  $g_i$  and  $h_i$  be indicators which are equal to one if consumer  $i$  is a member of group  $g$  or  $h$ , respectively.

Consumers enter the period enrolled in plan  $k$ . We define three indicators  $S_{sij}$  to capture the

**Table 3: Medicare beneficiary micro-data summary statistics**

Variable	All observations		By MA enrollment		TM → MA switch	
	Mean	Std. dev.	MA	TM	Yes	No
MA enrollment indicator	.226	.418	1	0	1	0
Income (\$)	46,535	68,736	38,168	48,982	39,707	44,387
Age	73.4	10.0	73.7	73.3	73.5	75.1
Medigap price (\$)	2,390	590	2,487	2,361	2,398	2,382
Demographic indicators						
Female	.536	.499	.549	.532	.540	.539
Black	.079	.270	.093	.075	.084	.068
Hispanic	.010	.100	.016	.008	.013	.007
Education indicators						
Bachelor's degree or higher	.236	.425	.178	.253	.211	.232
Attended college	.304	.460	.310	.302	.304	.291
Graduated high school	.291	.454	.310	.286	.298	.301
Health status indicators						
Excellent	.173	.379	.169	.174	.175	.160
Very Good	.309	.462	.320	.306	.318	.303
Good	.302	.459	.302	.302	.313	.315
Fair	.155	.362	.158	.154	.145	.161
Poor	.060	.237	.051	.062	.049	.061
Administrative indicators						
Employer-provided insurance	.330	.470	.011	.423	.000	.434
Non-aged eligibility	.159	.365	.164	.157	.188	.160
ESRD	.007	.081	.004	.007	.002	.007
Full-year Part A/B enrollee	.898	.302	.975	.876	.970	.898
Observations	58,444		13,225	45,219	994	22,284

Notes: An observation is a person-year. Statistics reported here are weighted according to sampling weights provided by the Medicare Current Beneficiary Survey (MCBS). Income and prices are in 2015 dollars. The outside good price is the United Healthcare premium for Medigap Plan C (see text for details). Demographic categories are defined by CMS administrative data. The first set of two columns reports means and standard deviations for all observations in the microdata. The third and fourth columns split the observations into those enrolled in MA and those enrolled in TM. The last two columns split the observations by switching behavior. Only those person-year observations for which we observed the individual enrolled in TM in last year's MCBS are included in the these last columns.

effects of this previous enrollment. Let  $S_{1ij}$  be equal to one if  $k$  is the outside good – we call this the *Medicare-to-MA* indicator. Let  $S_{2ij}$  – the *MA Interfirm* indicator – be one if  $k$  is offered by a different firm than  $j$ . Finally, let  $S_{3ij}$  – the *MA Intrafirm* indicator – be one if  $k$  is offered by the same firm as  $j$  but  $k$  and  $j$  are different products.

Let  $u_{ijmt}$  denote the consumer’s utility from enrolling in a particular plan  $j$ . Dropping the market and time subscripts, the choice specific utility for MA plans is given by:

$$u_{ij} = \left( \alpha + \sum_g \alpha_g g_i \right) p_j + \beta_h \sum_h oopc_{hj} h_i + \sum_s \beta_s S_{sij} + \sum_s \sum_h \beta_{sh} S_{sij} h_i + \beta_z z_i + \beta X_j + \xi_j + \epsilon_{ij} \quad (3)$$

In this equation,  $\alpha + \alpha_g$  captures price sensitivity for income group  $g$ .  $\beta_h$  captures the impact of expected out-of-pocket costs for that consumer’s specific age-health group  $h_i$ .  $\beta_{sh}$  captures switching costs and varies by health group.  $\beta_z$  captures heterogeneous tastes for MA versus TM.  $\beta$  captures mean tastes for plan characteristics  $X_j$ .

As is standard in random utility demand systems, we decompose the unobservable (to the econometrician) portion of utility into two components.  $\xi_j$  represents the portion of unobserved plan utility that is common across individuals.  $\epsilon_{ij}$  represents the idiosyncratic taste of consumer  $i$  for plan  $j$  which is assumed to be drawn independently from the Type-I extreme value distribution.<sup>15</sup>

We allow the utility of the outside good to vary with the price schedule of supplemental insurance  $\{p_0\}$ , which we denote at the individual level by  $p_{0i}$ , through

$$u_{i0} = \beta_0 p_{i0} + \epsilon_{i0}. \quad (4)$$

We normalize the outside good by subtracting  $\beta_0 p_{i0}$  from each  $u_{ij}$ .

We include switching costs due to the consistent finding of inertia in plan enrollment (Nosal, 2012, Aizawa and Kim, 2018).<sup>16</sup> Enrollees in MA face a different set of benefits and provider networks than in TM and those details vary across insurers and plans. Switching between plans entails learning about administrative procedures and provider networks. In addition, Medicare

<sup>15</sup>We have explored demand systems with persistent idiosyncratic tastes and found similar results.

<sup>16</sup>Like Aizawa and Kim (2018), we do not model consumers as dynamic for several reasons. First, such analysis is computationally intensive. Second, it likely requires assuming that individuals choose according to a model of neoclassical preferences with a discount factor close to one. However, recent work has shown that in related settings that model does not explain Medicare beneficiary behavior well (e.g. Dalton et al., 2018). Third, Nosal (2012) estimates such a model and finds extremely high (perhaps implausibly so) switching costs. Fourth, our estimation approach captures the inertia that is salient for our counterfactual analysis.

beneficiaries are automatically re-enrolled in their previous plan if they take no action during their open enrollment period – it is virtually costless to re-enroll. Similar to Handel (2013), we model these costs with a direct utility impact through the  $\sum_s \beta_s S_{sij}$  term.<sup>17</sup>

The vector of plan characteristics  $X_j$  includes the the plan’s deductible, out-of-pocket limit, copay and coinsurance rates, indicators for supplemental coverage, and the other characteristics included in Table C.1. We also include the Part B premium reduction in  $X_j$  as consumers may respond differently to rebates than they do to premiums – a ‘kinked’ demand response similar to that of Curto et al. (2018). However, the presence of the expected out-of-pocket costs, which are calculated by CMS in part as a function of these product characteristics, changes the interpretation of the  $\beta$  coefficient –  $\beta$  captures the mean taste for plan features conditional on the overall level of out-of-pocket expenditures.

Following Berry et al. (1995), it is useful to rewrite the utility  $u_{ij}$  into a product-level mean

$$\delta_j = \alpha_0 p_j + \beta X_j + \xi_j \quad (5)$$

and an individual-specific deviation from that mean

$$\mu'_{ij} = \sum_g \alpha_g g_i p_j + \sum_h \beta_h oopc_{hj} h_i + \sum_s \beta_s S_{sij} + \sum_s \sum_h \beta_{sh} S_{sij} h_i + \beta_z z_i - \beta_0 p_{i0} + \epsilon_{ij}. \quad (6)$$

Let  $\mu_{ij} = \mu'_{ij} - \epsilon_{ij}$ . Given our distributional assumption on  $\epsilon_{ij}$ , the probability that consumer  $i$  chooses plan  $j$  (i.e. the share function) is a logit form

$$s_{ij} \equiv \Pr(i \text{ chooses } j) = \frac{\exp(\delta_j + \mu_{ij})}{1 + \sum_{k \in \mathcal{J}_m} \exp(\delta_k + \mu_{ik})}. \quad (7)$$

The consumer surplus for an individual  $i$  given prices and product characteristics is

$$CS_i = E[\max_j u_{ij}] / \alpha_i = \frac{1}{\alpha_i} \ln \left( 1 + \sum_j \exp(\delta_j + \mu_{ij}) \right) \quad (8)$$

where  $\alpha_i$  is the price sensitivity of  $i$ . As in Section 3, this is the amount  $i$  would be willing to pay to have the choice of MA plans, relative to a world in which TM was the only option – it does not include the benefit of TM itself.

---

<sup>17</sup>If an enrollee’s previous plan is no longer available and the enrollee does not select a plan, the previous insurer may ‘crosswalk’ the enrollee to the most similar offered plan. We set intra-firm switching costs to zero in these cases.

## 5.2 Supply

Firms start each period with common knowledge of the distribution of consumer demographics, including enrollment status, the per-enrollee subsidy they receive  $B_j$ , and each others costs.<sup>18</sup> We model marginal costs as log-linear in observed characteristics  $r_j$  (which includes  $X_j$  and  $oopc_j$  and possibly other observables) and some unobserved (to the econometrician) component  $\omega_j$  with

$$\ln(mc_j) = \gamma_r r_j + \omega_j. \quad (9)$$

Given these costs and the demand model above, the profit maximization problem for firm  $f$  is

$$\max_{\{p_f, X_f, oopc_f, \xi_f\}} \pi_f = \sum_{j \in \mathcal{J}_f} \left[ (p_j + B_j - mc_j) \int_i s_{ij}(p, X, oopc, \xi; \theta) di \right]. \quad (10)$$

This maximization problem is written with respect to the set of vectors  $\{p_f, X_f, oopc_f, \xi_f\}$  to indicate that firms choose these attributes for all of their products simultaneously.<sup>19</sup>  $s_{ij}$  depends on the characteristics of all products in the market;  $\theta$  is the vector of demand system parameters.

## 6 Estimation

We estimate the parameters of the demand system following the approach of Goolsbee and Petrin (2004). First, we estimate parameters which capture individual-level variation – those parameters that define  $\mu'_{ij}$  – with a maximum likelihood approach. We then estimate the parameters common to individuals – those parameters that define  $\delta_j$  – with an instrumental variables approach.

Let  $\theta_I = \{\alpha_g, \beta_h, \beta_s, \beta_{sh}, \beta_z, \beta_0\}$  be the set of parameters which comprise  $\mu'_{ij}$ . For a given candidate value  $\tilde{\theta}$  we use the Berry (1994) inversion and find the unique set of product fixed effects  $\delta_j(\tilde{\theta})$  that match predicted shares to observed market shares. Let  $C_{ij}$  be an indicator variable that is equal to one if person  $i$  chose product  $j$ .<sup>20</sup> We form the likelihood function

$$L_i(C_{ij}; \tilde{\theta}, \delta(\tilde{\theta})) = \prod_j s_{ij}^{C_{ij}}, \quad (11)$$

<sup>18</sup>We do not explicitly model bidding though we account for it in our counterfactual approach. See Section 7.

<sup>19</sup>In practice, firms do not directly choose each of the OOPC measures as they are calculated by CMS. The plan characteristics we observe capture 38% of the variation in the OOPC measures and therefore it is practical to model these as separate choices made by firms rather than as functions of other observables.

<sup>20</sup>Calculating  $C_{ij}$  involves two complications. First, the variables in the MCBS vary from year to year and we are not always able to recover a unique choice. Second, we model utility as a function of past enrollment, and the rolling panel design implies that a fraction of our observations have no past enrollment data. We address this by eliminating plans given what we do observe and taking draws from the conditional shares of the remaining products.

where  $s_{ij}$  is given by Equation 7. In the first stage of our estimation procedure, we apply the MCBS sample weights  $w_i$  and maximize the weighted log likelihood function

$$l(C; \tilde{\theta}) = \sum_i \ln(L_i)w_i, \quad (12)$$

At the point estimate  $\hat{\theta}$  we store the unique  $\hat{\delta}_j$  and regress it on observable product characteristics according to Equation 5. We recover marginal cost parameters by inverting the firms’ first-order conditions for price and estimating Equation 9.

## 6.1 Identification

Since  $\xi_j$  is observed by firms but not by us, it is likely to be correlated with the price and other characteristics of the plan. To identify the coefficients  $\alpha_0$  and  $\beta$ , we make the common assumption that the unobservable product characteristic  $\xi_j$  is uncorrelated with the observed product characteristics  $X_j$ . This implies both that  $\beta$  is identified and that instruments formed as functions of the  $X_j$  are valid for price — we use the summation instruments of Berry et al. (1995).

One potential concern is the fact that firms choose  $\xi_j$  and  $X_j$  simultaneously as a function of the benchmark, which implies that these characteristics may be correlated through this mutual dependency. Our data captures a wealth of detail about plan benefits, and thus the largest components of  $\xi$  are likely to be local network breadth, advertising (which may occur at the local or regional level), and unobservable quality. These are unlikely to change in response to small changes in the benchmark, and thus it is reasonable to assume that  $\xi_j$  is uncorrelated with  $B_j$ . We test this by estimating  $\hat{\xi}_j$  and computing its correlation with  $B_j$ . Some of the components of  $\xi_j$  are likely to be constant across plans within a given firm<sup>21</sup>, and so we include firm fixed effects in  $X_j$ .

Firms face state and federal regulations which change over time suggesting there may be some component of marginal cost which is constant across firms within a state-year. Following the logic of Hausman et al. (1994) we use average prices in other counties as additional price instruments. Since plans are often offered at the same price in geographically contiguous counties, we calculate this instrument using “non-contiguous counties” – that is, for a plan in a county, we calculate the average price of plans in counties of the same state which do not share borders with the county under consideration.

Just as  $\xi_j$  is likely to be correlated with  $p_j$ , it is also likely to be correlated with firm costs.

---

<sup>21</sup>Indeed, Aizawa and Kim (2018) make the assumption  $\xi_j = \xi_f$  for all plans offered by the same firm.

However, after estimating the demand parameters, we can calculate a  $\hat{\xi}_j$  for each plan and include it in  $r_j$ . We estimate Equation 9 by assuming that any unobservable components of cost are uncorrelated with  $\hat{\xi}_j$  and our observables.

## 6.2 Demand results

Maximum likelihood parameter estimates are reported in Table 4. High and medium income consumers are less price sensitive than low income consumers. Out-of-pocket costs create disutility, while an increase in the cost of Medigap drives consumers to MA plans. Non-White individuals have a stronger preference for MA plans, as do individuals with lower levels of education. Our administrative indicators enter with appropriate signs and reasonable magnitudes.

The bottom rows of Table 4 report switching cost parameters. We interact each switching cost with indicators for self-reported health status, with ‘Poor’ as the excluded group. The highest costs are incurred by consumers switching from TM to MA. Inter-firm switches are less costly and intra-firm switches are cheaper still. These results suggest the primary component of switching costs is the disutility of changing providers. While being in better than ‘Poor’ health appears to have an impact on the costs of switching from TM to MA, the interaction terms do not enter with significance for either of the other switching cost types.

Table 5 reports estimates of Equation 5. The first column presents the OLS estimates and the second presents IV results. Consistent with OLS estimates on price being biased towards zero, the IV price coefficient is larger in magnitude than the OLS coefficient. For this reason, we concentrate our attention on the IV specification.<sup>22</sup> These estimates in general correspond to sensible priors. For the plans with a positive premium the average plan elasticity is -2.66.<sup>23</sup> The average semi-elasticity of increasing premiums \$1 is .3 percent, similar to estimates from the literature. For example, using an earlier sample period, Aizawa and Kim (2018) estimate an average MA semi-elasticity of .75 percent. We also test the null hypothesis that  $\xi_j$  is uncorrelated with  $B_j$ . The empirical correlation coefficient is  $-0.0025$  and so we cannot reject the null hypothesis.

The presence of CMS OOPC estimates in the first stage, which are in part a function of these variables, changes the interpretation of these parameters. The parameters estimated here are not

---

<sup>22</sup>We do not include star ratings in this specification for two reasons. First, they are generally calculated at the firm level, and so are largely picked up by firm fixed effects. Second, CMS changed the definition of the ratings several times throughout the sample period, increasing the noise in the measure.

<sup>23</sup>An important issue in the proposed Aetna-Humana merger was the rate of substitution between MA and TM if insurers were to increase premiums. We find that a \$100 increase in all plan premiums (or \$8.33 per month), holding everything else constant, results in a 5.6% shift in enrollees from MA to traditional Medicare.



**Table 4: Maximum likelihood estimates of individual-specific preferences**

Variable	Coefficient	Std. Err.
Income-price interaction (per \$1000)		
Medium income	0.153	0.039
High income	0.089	0.042
Estimated OOPC (per \$1000)	-0.038	0.024
Medigap price (per \$1000)	0.218	0.046
MA × Demographics		
Age	1.704	0.153
Age <sup>2</sup>	-0.118	0.010
Female indicator	-0.035	0.028
Black indicator	0.317	0.055
Hispanic indicator	0.130	0.132
Graduated high school	-0.078	0.043
Attended college	-0.165	0.043
College degree or higher	-0.514	0.047
Administrative indicators		
Has employer-provided insurance	-3.649	0.089
Non-aged eligibility	0.318	0.048
ESRD diagnosis	-0.933	0.196
Full year Medicare enrollment	1.778	0.061
TM-to-MA switch ×		
Constant	-2.892	0.088
Excellent health	0.193	0.102
Very good health	0.258	0.094
Good health	0.146	0.084
Fair health	0.132	0.078
Inter-Insurer switch ×		
Constant	-1.627	0.129
Excellent health	0.011	0.152
Very good health	0.113	0.140
Good health	0.032	0.139
Fair health	-0.007	0.147
Intra-Insurer switch ×		
Constant	-0.515	0.152
Excellent	-0.089	0.177
Very good	0.006	0.165
Good	-0.005	0.165
Fair	0.033	0.173
Weighted Log Likelihood	-58,148	
Obs.	58,444	

Notes: This table reports maximum likelihood estimates of the individual-specific components of Equation 3. In the estimation, each individual receives the estimated out-of-pocket cost (OOPC) for their age-health demographic group (e.g. 70-74 Good). Income groups are defined by terciles of the income distribution for the entire MCBS sample; low income is the omitted group. The omitted group for the switching cost interactions is ‘Poor’ health. We weight the likelihood function using the MCBS sample weights to obtain nationally representative estimates.

the direct effect of these features *per se*, but rather their impact on utility holding expected OOPC constant. In that light, our results indicate that consumers prefer to incur out-of-pocket costs on copays and coinsurance, rather than deductibles. Consumers prefer expenditures on plan benefits to reductions in Medicare Part B premiums. While prescription drug coverage is valued by consumers, vision and dental coverage isn't. PPOs are preferred to HMOs.

Appendix Table C.3 reports the mean switching cost by type and income group calculated by dividing the switching cost coefficients by the price coefficient for each person. The cost incurred by an average medium-income individual switching from TM to MA is \$918, which is almost twice the mean annual premium in our data, while the same average individual switching between plans within an MA insurer incurs a cost of only \$177, about a third of the average annual premium.

Table 6 reports estimates of Equation 9. As the OOPC measures for different groups are highly collinear we focus on the median OOPC, the measure for a 65-69 year old in Good health – the results are similar when using alternative OOPC measures. We include firm and county fixed effects to focus on the costs of different plan designs and to account for costs which stem from geography. The major cost sharing plan design parameters, including the OOPC, deductibles, and out-of-pocket limits, enter with the correct sign. Offering prescription drugs increases costs by 3.9%. The coefficient on the demand unobservable is positive and significant at the 1% level, suggesting that specifications which did not take the correlation between demand and cost unobservables into account would be biased. As with the demand system, the copay and coinsurance parameters must be interpreted in the context of the overall OOPC parameter. HMOs face lower costs than PPOs.

There has been some discussion about the usefulness of structural techniques for estimating costs and counterfactual outcomes (e.g. Angrist and Pischke, 2010, Nevo and Whinston, 2010). Criticism has focused on the use of demand elasticities and first-order conditions to calculate marginal costs. In our setting, CMS reports the actual risk-adjusted per-capita TM expenditures in each market, which, if our estimation approach is consistent, are likely to be correlated with our estimated marginal costs. We mimic the spirit of an exercise in Curto et al. (2018, fig. 4) and compare the share-weighted estimated MA cost to TM costs at the county level for 2015 in Appendix Figure C.3. The two cost measures are positively correlated with a coefficient of .527; on average, estimated MA costs are lower than TM costs.

**Table 5: Estimates of mean preferences for plan characteristics**

Variable	OLS	IV
Annual premium (per \$1000)	-.116 (.016)	-3.11 (.452)
Part B reduction (per \$1000)	-.000 (.000)	-.008 (.003)
Deductible (per \$1000)	-.055 (.323)	-1.50 (.157)
Out-of-pocket limit (per \$1000)	.020 (.004)	-.094 (.028)
Coverage indicators		
Prescription drugs	.539 (.023)	2.59 (.177)
Vision	-.199 (.032)	-.952 (.341)
Dental	-.133 (.020)	-.207 (.177)
Copays		
Primary doctor	-.014 (.002)	.109 (.017)
Specialist	.016 (.001)	.067 (.007)
Hospital stay (per \$1000)	.040 (.060)	.432 (.584)
Coinsurance		
Primary doctor	.015 (.005)	.055 (.012)
Specialist	-.014 (.006)	.145 (.021)
Hospital stay	.015 (.011)	-.040 (.023)
HMO indicator	.256 (.026)	1.72 (.577)
PPO indicator	.433 (.032)	4.22 (.389)
Fixed effects	None	Firm-level
Mean implied elasticity (if < 0)	-.018 (.036)	-2.66 (1.78)
Mean $ds_j/dp_j$	-.000 (.001)	-.033 (.060)
Observations	50,593	50,593

Notes: This table reports estimates of the plan-specific components of Equation 3. To form these estimates, we first use maximum likelihood estimation to recover the parameters in Table 4, calculate plan fixed effects  $\delta_j$ , and then regress these fixed effects on plan observables via Equation 5. Observations are at the market-plan level. The IV specification uses the summation instruments of Berry et al. (1995) and our ‘non-contiguous county’ variation of Hausman instruments. Robust standard errors are in parentheses.

**Table 6: Marginal cost parameter estimates**

Variable	$\ln(mc_j)$
Deductible (per \$1000)	-.016 (.001)
OOP limit (per \$1000)	-.003 (.000)
OOP cost estimate (per \$1000, 65-69, Good)	-.011 (.000)
Demand unobservable ( $\xi_j$ )	.011 (.000)
Coverage indicators	
Prescription drugs	.038 (.001)
Vision	-.005 (.001)
Dental	.007 (.001)
Copays	
Primary doctor	.002 (.000)
Specialist	.000 (.000)
Hospital stay (per \$1000)	-.034 (.002)
Coinsurance	
Primary doctor	-.000 (.000)
Specialist	.003 (.000)
Hospital stay	.003 (.002)
HMO indicator	-.038 (.001)
PPO indicator	.036 (.001)
Fixed effects	Firm, county
Observations	50,593
$R^2$	.749

Notes: This table reports the results of estimating Equation 9, where the left-hand side variable comes from inverting the first-order conditions for price of Equation 10 at the demand parameters presented in Tables 4 and 5. Estimates are formed via OLS. Robust standard errors are in parentheses. OOP stands for “out-of-pocket.” Observations are at the plan-market level.

## 7 Optimal Geographic Variation in Medicare Advantage Subsidies

We now turn to the problem of setting the benchmark rates to maximize the consumer surplus generated by MA keeping government expenditures constant. To update the notation of Equation 1 to our full model, let  $B_m$  be the benchmark rate for a particular market,  $CS_{im}(B)$  be the equilibrium consumer surplus for consumer  $i$  in market  $m$  when the benchmark rate is  $B$ , and  $GovExp_m(B)$  be the equilibrium total government expenditures on the Medicare program in market  $m$  including both TM and MA.  $\bar{B}$  is the total budget available to the government. We consider three types of optimal subsidy problems given by

$$\max_{\{B_m\}} \sum_m \int_i CS_{im}(B_m) di \quad \text{s.t.} \quad \sum_m GovExp_m(B_m) = \bar{B} \quad (13)$$

$$\max_{\{B_m\}} \alpha \sum_m \int_i CS_{im}(B_m) di - (1 - \alpha) Var(CS) \quad \text{s.t.} \quad \sum_m GovExp_m(B_m) = \bar{B} \quad (14)$$

$$\min_{\{B_m\}} \sum_m GovExp_m(B_m) \quad \text{s.t.} \quad B_m \geq \bar{B}_m \forall m \quad (15)$$

The first equation maximizes consumer surplus subject to a government budget constraint and is analogous to Equation 1. As we document below, the solution creates winners and losers across markets which may not be politically feasible to implement. For this reason, Equation 14 penalizes the variance in consumer surplus across individuals –  $\alpha \in [0, 1]$  determines the relative weight on consumer surplus versus the variance in consumer surplus. We also search for a “Pareto improving” policy with Equation 15 by minimizing government expenditures subject to the constraint that benchmarks in each market (and therefore consumer surplus) stay at least at the level of current policy represented by  $\bar{B}_m$ .

Solving these problems requires calculating the  $CS$  and  $GovExp$  functions. Given prices and product characteristics as a function of  $B_m$ ,  $CS(B_m)$  comes from Equation 8. Expenditures are

$$GovExp(B_m) = \int_i \left[ \sum_j s_{ij} Payment_{jm} + \left( 1 - \sum_j s_{ij} \right) TM_m \right] di, \quad (16)$$

where  $Payment_{jm}$  is the plan-level payment of Equation 2,  $s_{ij}$  is the share function of Equation 7, and  $TM_m$  is the average per-enrollee TM spending in the market. As we do not observe individual-specific risk scores, we calculate MA and TM spending using the average risk level in the market — in other words, we set  $RiskAdjustment_{it} = RiskAdjustment_{mt}$  in Equation 2 for all  $i$ . We treat

$TM_m$  as exogenous due to the risk adjustment system – MA enrollment patterns do not change average risk-adjusted TM spending. Since the benchmark and rebate adjustment terms,  $\phi_{jt}$  and  $\lambda_{jt}$ , are determined by previous firm performance, we take them as given.

## 7.1 An equilibrium approximation approach to counterfactual analysis

The inputs to  $CS$  and  $GovExp$  are prices and product characteristics in each market as a function of the benchmark. A traditional counterfactual approach would derive policy functions by varying the benchmark and searching for Nash equilibria, usually through analyzing firms’ first-order conditions for profit maximization. For example, Fan (2013) uses this approach to find a post-merger equilibrium in prices and five product characteristics in a daily newspaper market with five competitors – a total of 30 first-order conditions. However, as each plan in our data has 48 characteristics and the average market has 14 plans, solving for a single equilibrium in one market involves a fixed point search across 672 first-order conditions requiring significantly greater computational effort (Daskalakis et al., 2009). To find an optimal policy, we must search over hundreds of equilibria in each of the 445 markets in the 2015 data, a computationally infeasible task.

Our alternative “equilibrium approximation” approach combines policy function estimation with a reduced-dimension fixed-point problem. Our approach hinges on observing variation in the benchmark – the key primitive we wish to change in the counterfactual – in the data both across markets and over time. As discussed above, CMS sets the benchmark each according to risk-adjusted TM expenditures alone and so the benchmark is exogenous from the firm’s perspective. Table 2 shows this variation in the benchmark comes with variation in observed product characteristics – the data trace out policy functions. To predict counterfactual characteristics, we regress observed characteristics on the benchmark (and other covariates) and use the fitted values at counterfactual benchmarks to update product characteristics. We then solve for prices in a Bertrand Nash game.

Our approach pools data from different markets and so we adopt the Equilibrium Selection (ES) assumption of Bajari et al. (2007): we assume that firms across markets play the same equilibrium strategies with respect to the benchmark. While this assumption may be concerning when markets are geographically isolated (Noel, 2007), our data is characterized by firms offering products in multiple overlapping geographies. We therefore conclude that the existence of isolated markets with widely disparate equilibrium behavior is unlikely.

We build on past efforts to use policy function estimation for counterfactual analysis. Goolsbee

and Petrin (2004) study competition between pay television systems and use estimated functions for prices and product characteristics to calculate the welfare improvement caused by the introduction of satellite TV. Benkard et al. (2018) estimate strategic entry and exit behavior in the airline industry and simulate industry outcomes under counterfactual merger scenarios. We extend these efforts by combining our estimated policy functions with our demand model to solve for a Nash equilibrium in prices and calculate the welfare effects of changes in the government policy.

We simplify the problem by defining a ‘price-adjusted quality’  $\delta'$  for each plan given by

$$\delta'_j = \delta_j - \alpha_0 p_j. \tag{17}$$

As firm costs and characteristics are asymmetric, it is unlikely that a symmetric equilibrium exists (Hefti, 2017). We therefore regress  $\delta'_j$  on the benchmark, firm fixed effects, and other variables designed to capture potential sources of asymmetry across plans. We include the ‘rank’ of  $\delta'_j$  with respect to the firm’s other plans to capture the fact that firms offer multiple plans with different levels of generosity at different price points, an indicator which is one if the insurer has the highest share in the market, and the total number of plans in the market. We use the same variables to capture variation in each of the OOPC terms.

Given a benchmark for a market, we use our estimated policy functions to calculate the new  $\delta$  and updated OOPC for each plan in that market. We take the difference between the estimated policy at the new benchmark and the estimated policy at the observed benchmark and apply that difference to the observed policy. This adds flexibility to our approximation and maintains plan-level heterogeneity without adding terms to our regressions. We apply a similar approach to other primitives by estimating marginal cost as a function of  $\delta'$  and OOPC, consistent with our model, and estimating the bid as a function of marginal cost, consistent with CMS bidding rules.

With the set of product characteristics, costs, and bids in hand, we calculate prices by iterating over the  $\frac{\partial s_j}{\partial p_j}$  matrix. We implement this solver with a non-negativity restriction on prices to capture the kink in the CMS payment design (Equation 2). These rules – using the differences in the policy functions and the non-negativity restriction on prices – make our counterfactual and estimation approaches consistent in the sense that when we calculate equilibria at the benchmarks in the data, the outcomes (prices, product characteristics, shares, etc.) match the data precisely.

To summarize, given a benchmark for a given county, we calculate  $CS_m$  and  $GovExp_m$  with the following steps:

1. Use the estimated policy functions to calculate  $\delta'_j$  and  $oopc_j$  for each plan.
2. Use the estimated marginal cost and bid functions with the new product characteristics to calculate  $mc_j$  and  $bid_j$ .
3. Taking as given these new characteristics and costs, solve for the new equilibrium in prices.
4. Given the new prices and characteristics, calculate consumer surplus with Equation 8 and government spending with Equation 16.

We now have the ingredients of the maximization problems posed by Equations 13, 14, and 15. As we find equilibria numerically, we cannot solve for the constraint surface analytically and instead we satisfy the constraint numerically using a penalty function. Across these problems, both the objective function and the constraint are non-linear and so we address the possibility of multiple local maxima with a multistart procedure inspired by Rinnooy Kan and Timmer (1987).

We do not model the impact of subsidies on plan entry and exit due to the computational effort required. However, incorporating entry and exit into the analysis should not significantly impact the results as the plans that enter and exit in our sample comprise a small share of the total MA market and thus contribute little to consumer surplus. The average share of exiters in the year before they exit is 0.62%. The average share of new entrants upon entry is 0.72% and the average share two years later is 1.1%. As our counterfactual benchmarks are within the support of the current benchmark distribution, the role (or lack thereof) of past entry and exit on consumer surplus should be informative about its impact on consumer surplus in the counterfactuals. Decarolis et al. (2015) use a similar logic in their analysis of Medicare Part D. Maruyama (2011) studies entry and pricing in Medicare+Choice but does not endogenize product characteristics.

## 8 Counterfactual results

We apply our approach to solve optimal subsidy problems for our 2015 sample. We present our estimated policy functions and then present our primary exercise in which we maximize average consumer surplus. We also discuss alternative objective functions.

### 8.1 Policy function estimates

Table 7 reports estimates of our policy functions. The first three columns focus on the  $\delta'$  policy function. Column (1) fits  $\delta'$  on the benchmark alone, and Column (2) adds insurer fixed effects.



**Table 7: Estimates of the price-adjusted quality and selected out-of-pocket cost policy functions**

	(1)	(2)	(3)	(4)	(5)	(6)
Variable	$\delta'$	$\delta'$	$\delta'$	OOPC 65-69 V. Good	OOPC 70-74 Good	OOPC 75-79 Fair
Benchmark	-.541 (.014)	-.248 (.015)	.030 (.012)	-.017 (.003)	-.059 (.005)	-.091 (.007)
Plan rank			-.982 (.008)	.098 (.002)	.148 (.003)	.236 (.005)
Leading insurer ind.			1.30 (.029)	-.083 (.008)	-.126 (.011)	-.179 (.017)
# plans in market			-.031 (.001)	-.008 (.000)	-.010 (.000)	-.013 (.000)
Fixed Effects	None	Firm	Firm	Firm	Firm	Firm
Observations	50,593	50,593	50,593	50,593	50,593	50,593
$R^2$	.034	.307	.514	.256	.240	.228

Notes: The independent variables are the  $\delta'$  defined by Equation 17 and the CMS OOPC estimates by age and health status. The benchmark is at the market level. The plan rank variable is the rank of the plan within its insurer, ordered by the value of the  $\delta'$ , with 1 as the top-ranked plan. The leading insurer indicator is equal to 1 if the firm has the highest total share in the market. Estimates are obtained via OLS. Robust standard errors are in parentheses.

Column (3), our preferred specification, controls for the rank of the plan, an firm-level indicator for high market share, and the number of plans in the market. The benchmark enters with a positive sign, and the  $R^2$  is .514.<sup>24</sup> Columns (4)-(6) report estimates for three OOPC policy functions using an analogous specification; Appendix Table C.4 reports estimates for all thirty OOPC. In general, increases in the benchmark lead to decreases in estimated OOPC, and these decreases are larger for those who are older and those in worse health.  $R^2$ s range from .210 to .312.

To complete our set of plan primitives, we regress marginal cost on product characteristics and the plan bid on the marginal cost. For both, we include insurer and county fixed effects. For consistency with our other estimates, the left-hand side variables are in levels.<sup>25</sup> The first column of Table 8 reports the parameter estimates for marginal cost. As with Table 6, we include only one OOPC for simplicity. Increasing the  $\delta'$  leads to an increase in the marginal cost, and increasing the OOPC decreases the marginal cost. The second column reports estimates for the bid. The coefficient on marginal costs is less than one, which is sensible given CMS bidding rules – in particular the requirement that bids reflect the cost of providing TM-equivalent benefits.

<sup>24</sup>For comparison, Goolsbee and Petrin (2004) report an  $R^2$  of .187 for their analogous exercise (Table 9), and Benkard et al. (2018) report pseudo- $R^2$ s ranging from .125 to .999 across a range of similar exercises.

<sup>25</sup>We repeated the counterfactual exercise with these functions in logs instead of levels and obtained similar results.

**Table 8: Estimates of the marginal cost and bid functions**

Variable	Marginal cost	Bid
$\delta'$	.146 (.001)	
OOPC 65-69 Good	-.112 (.003)	
Marginal cost		.918 (.006)
Fixed Effects	Insurer, County	Insurer, County
Observations	50,593	50,593
R-squared	.779	.489

Notes: Each column of this table reports the results of an OLS regression. The independent variable in the first column is the marginal cost estimate obtained through inverting the first-order conditions of Equation 10. The independent variable in the second column is the plan bid for an individual of 1.0 risk from the CMS data.  $\delta'$  is the price-adjusted  $\delta$  of Equation 17. Robust standard errors are in parentheses.

## 8.2 Maximizing consumer surplus

Table 9 reports the results of our primary counterfactual exercise. The first column reports surplus under the 2015 policy across a number of dimensions. The mean consumer surplus unconditional on MA enrollment is \$148.65. The MA program generates a total of \$5.94 billion in consumer surplus per year. The second column reports the results of solving Equation 13 and the third column calculates percentage changes between the two policies. The optimal policy increases mean surplus by 29.6% to \$192.65; the aggregate surplus increases to \$7.70 billion. These changes are driven more by the total share of MA, which increases 23.6% from 26.7% to 33.0%, than by the consumer surplus conditional on enrollment, which increases 4.99% from \$556.02 to \$583.74.<sup>26</sup>

The second panel of Table 9 splits markets by the direction of the benchmark change relative to the 2015 policy. The optimal policy increases the benchmark in 334 out of the 445 markets in our sample, and in those markets the mean surplus increases from \$124.09 to \$200.99, while in the 111 markets where the benchmark is lower, the mean surplus decreases from \$222.40 to \$167.61. In other words, the optimal policy improves upon the 2015 policy by increasing the consumer surplus where the existing surplus is low, rather than areas where existing surplus is high.

The third panel examines the changes by demographic groups. White consumers receive a greater increase in mean consumer surplus than do Black consumers, while Hispanic consumers experience a decrease. Changes are roughly constant across income groups.

<sup>26</sup>Appendix Table C.7 reports firm-level market shares and total variable profits under the 2015 policy, the optimal policy, and other policies explored below.

**Table 9: Average annual surplus and market share under the 2015 policy and the optimal policy**


	2015 Policy	Optimal Policy	Percentage Change
Mean CS, unconditional on MA enrollment (\$)	148.65	192.65	29.6
Total MA share (%)	26.7	33.0	23.6
Mean CS, conditional on MA enrollment (\$)	556.02	583.74	4.99
Total consumer surplus (\$ billion)	5.94	7.70	29.6
<i>Mean unconditional consumer surplus by direction of benchmark change</i>			
334 markets with benchmark increases (\$)	124.09	200.99	62.0
111 markets with benchmark decreases (\$)	222.40	167.61	-24.6
<i>Mean unconditional consumer surplus by demographic group</i>			
White consumers (\$)	145.67	191.01	31.1
Black consumers (\$)	167.90	203.90	21.4
Hispanic consumers (\$)	262.13	249.86	-4.68
Low income consumers (\$)	166.59	213.74	28.3
Medium income consumers (\$)	155.37	203.57	31.0
High income consumers (\$)	125.64	162.80	29.6

Notes: This table reports results of the solution to the optimal subsidy problem presented in Section 7. The first column reports data for the 2015 policy. The second column reports the results of maximizing consumer surplus per Equation 13. Consumer surplus is calculated via Equation 8; surplus figures are in dollars per Medicare-beneficiary-year. White, Black, and Hispanic groups are defined by CMS. All results are weighted by MCBS sample weights.

The benchmark changes are detailed in Figure 2. The left-hand histogram illustrates the distribution of benchmarks under the optimal policy, and can be compared to Appendix Figure C.1. The right-hand histogram shows the distribution of changes in the benchmark. The changes are generally modest – the interquartile range of the difference between the optimal and 2015 benchmarks is from \$0 to \$658. The mean change is \$330 and the median is \$267. In percentage terms, over 90% of the changes in the benchmark are of less than 10% than the 2015 benchmarks.

The magnitude of the changes in the mean surplus across markets in which the benchmark increases and markets in which the benchmark decreases suggests that the aggregate changes in these markets are also substantial. Table 10 reports the aggregate consumer surplus and government spending on TM and MA under the 2015 policy and the optimal policy, split by the direction of the optimal policy change. The aggregate consumer surplus increases in markets with benchmark increases from \$3.72 billion per year to \$6.03 billion per year. This change comes with a decrease in spending on TM from \$235.2 billion to \$202.5 billion, and an increase in MA spending from \$66.2

**Figure 2: The distribution of the optimal benchmarks by market**



Notes: These graphs illustrate the solution of Equation 13. The left-hand graph shows the distribution of benchmarks under the optimal policy and the right-hand graph illustrates the distribution of the change in benchmarks from the 2015 policy to the optimal policy.

billion to \$99.7 billion.<sup>27</sup> Aggregate consumer surplus decreases in the other markets from \$2.22 billion to \$1.67 billion, while spending transfers from MA to TM.

The construction of our optimal subsidy problem implies that markets should be selected for increases and decreases based upon the marginal impact of an increase in the benchmark rate on consumer surplus and government expenditures. Table 11 reports the distribution of the derivatives of consumer surplus, government expenditures, and total surplus (defined as consumer surplus minus government expenditures) with respect to a \$1 increase in the benchmark rate. The first subtable focuses on markets in which the benchmark increases, and the second subtable focuses on benchmark decreases. Within each, the top panel presents derivatives of the surplus and spending unconditional on MA enrollment, while the bottom panel conditions on MA enrollment.

The distributions of both the conditional and unconditional consumer surplus derivatives overlap across the groups of markets, suggesting that potential changes in consumer surplus alone do not drive the results. In contrast, both the distributions of the derivatives of government expenditures in isolation and the distributions of the total surplus derivatives are more separated across the two sets of markets. Indeed, of the 334 markets with benchmark increases, 228 have positive total surplus derivatives, and every market with a benchmark decrease has a negative total surplus derivative. In Appendix B, we explore the non-local behavior of our surplus and spending functions.

Given the importance of these derivatives to determining the direction of benchmark changes, a

<sup>27</sup>This transfer of resources from TM to MA may generate concerns about externalities with respect to the government’s bargaining power. However, as the government largely sets Medicare reimbursement rates nationally, with local cost-of-living adjustments, these externalities are likely to be small over the range of TM and MA enrollment shares estimated in our counterfactuals.

**Table 10: Aggregate market share, annual surplus, and spending under 2015 policy and optimal policy by direction of optimal policy change**

Markets in which benchmark increases (334 markets, 75.0% population share)			
	2015 Policy	Optimal Policy	% Change
Total MA share (%)	24.2	34.5	42.6
Total consumer surplus (\$ billion)	3.72	6.03	62.1
Spending on Traditional Medicare (\$ billion)	235.2	202.5	-13.9
Spending on Medicare Advantage (\$ billion)	66.2	99.7	50.6
Markets in which benchmark decreases (111 markets, 25.0% population share)			
	2015 Policy	Optimal Policy	% Change
Total MA share (%)	34.4	28.4	-17.4
Total consumer surplus (\$ billion)	2.22	1.67	-24.8
Spending on Traditional Medicare (\$ billion)	58.6	64.0	9.22
Spending on Medicare Advantage (\$ billion)	31.5	25.3	-19.7

Notes: Units are billions of 2015 dollars per year. All numbers are calculated from individual-level data, aggregated using the MCBS sample weights.

natural question is the extent to which market-level observables can explain the variance we see in these benchmarks. In addition to our county-level measures of TM costs, the number of Medicare beneficiaries, and the number of MA firms, we obtain county-level data from the U.S. Department of Health and Human Services’ Area Health Resources File (AHRF). The AHRF combines data from a number of U.S. government and non-profit sources to provide a detailed view of health-relevant information at the county-year level. We collect median household income, the percentage of seniors in severe poverty, the unemployment rate, population density, and per-capita counts of MDs, hospitals, skilled nursing facilities, and hospice facilities. We also collect the hospital readmission rate for Medicare patients and the “preventable” hospital admission rate.<sup>28</sup>

We model the market-level derivatives of the consumer surplus and government expenditure functions as a linear function of these observables. Columns (1) and (2) of Table 12 present standardized regression coefficients when the dependent variable is the derivative of consumer surplus and government expenditures, respectively. Across the two regressions, TM costs, measures of competition, income, and risk appear as strongly related to the derivatives. In total this model explains 31% (55%) of the variance in the derivative of consumer surplus (government expenditures).

A related question is the extent to which these variables can be used to generate linear policy rules. Column (3) of Table 12 uses the same observables to model the optimal benchmark in each

<sup>28</sup>Appendix Table C.5 reports the means of these variables by benchmark quartile for the 2015 and optimal policies.

**Table 11: Derivatives of surplus and spending functions with respect to a \$1 benchmark increase at 2015 policy by direction of optimal policy change**

Markets in which benchmark increases (334 markets, 75.0% pop. share)				
<i>Unconditional on MA enrollment</i>				
	Mean	25th %-ile	Median	75th %-ile
Consumer surplus (\$)	.084	.033	.065	.117
Government expenditures (\$)	.062	-.034	.049	.155
$(CS - GovExp)$ (\$)	.022	-.079	.026	.112
<i>Conditional on MA enrollment</i>				
	Mean	25th %-ile	Median	75th %-ile
Consumer surplus (\$)	.402	.215	.477	.569
Government expenditures (\$)	.058	-.266	.276	.553
$(CS - GovExp)$ (\$)	.344	-.23	.155	.763
Markets in which benchmark decreases (111 markets, 25.0% pop. share)				
<i>Unconditional on MA enrollment</i>				
	Mean	25th %-ile	Median	75th %-ile
Consumer Surplus (\$)	.108	.047	.075	.155
Government Expenditures (\$)	.297	.183	.243	.333
$(CS - GovExp)$ (\$)	-.189	-.252	-.141	-.076
<i>Conditional on MA enrollment</i>				
	Mean	25th %-ile	Median	75th %-ile
Consumer Surplus (\$)	.369	.163	.362	.550
Government Expenditures (\$)	.890	.722	.815	1.05
$(CS - GovExp)$ (\$)	-.522	-.624	-.511	-.362

Notes: Derivatives are calculated at the individual level and are weighted by the MCBS sample weights.

county. The optimal benchmark is most strongly associated with measures of competition, cost, and income.<sup>29</sup> Table 13 compares the optimal policy to the policy generated by the fitted values of this regression. The linear rule reduces consumer surplus relative to the optimal policy by 4.4%, and increases government spending by 0.5%. Under this rule, 317 markets receive benchmark increases, and 128 markets receive benchmark decreases. The second panel of Table 13 shows that, in general, the linear rule results in increases and decreases that are “too large” relative to the optimal policy; consumers in markets which receive increases (decreases) receive even more (less) surplus than under the optimal policy.

The differences between the optimal policy and the 2015 policy may have political economy

<sup>29</sup>We include the number of firms offering plans but do not include the number of plans due to endogeneity concerns.

**Table 12: Modelling the optimal policy and the derivatives of surplus and spending at the 2015 policy as a function of market-level observables**

	(1)	(2)	(3)
	Consumer Surplus	Government Expenditures	Log Optimal Benchmark
Log of Risk-adj. per-cap. TM costs	-.325 (.058)	-.630 (.044)	.080 (.002)
Number of MA firms	-.012 (.064)	.303 (.049)	-.009 (.003)
Log of Medicare beneficiaries	.174 (.086)	-.003 (.065)	-.010 (.003)
Share of 65+ population who is White	-.237 (.178)	-.034 (.135)	-.005 (.007)
Share of 65+ population who is Black	-.446 (.143)	-.101 (.109)	.000 (.006)
Share of 65+ population who is Hispanic	-.297 (.110)	.138 (.084)	.004 (.004)
Average risk score	.168 (.074)	.294 (.056)	-.000 (.003)
Log of median household income	-.013 (.079)	.040 (.060)	.001 (.003)
Share of 65+ population in deep poverty	-.120 (.053)	.032 (.040)	-.007 (.002)
Unemployment rate	-.018 (.060)	-.112 (.046)	.005 (.002)
Population density	.077 (.055)	-.078 (.042)	-.000 (.002)
MDs per capita	.064 (.062)	-.077 (.048)	.004 (.003)
Medicare-qualified hospitals per capita	-.025 (.047)	.012 (.0360)	-.000 (.002)
Nursing facilities per capita	.011 (.057)	-.085 (.043)	-.002 (.002)
Hospice facilities per capita	.017 (.047)	-.013 (.036)	-.000 (.002)
Medicare hospital readmission rate	.051 (.062)	.019 (.048)	.002 (.003)
Constant			2.247 (.002)
Observations	445	445	445
R-squared	.193	.533	.826

Notes: The independent variables have been normalized to have mean zero and unit variance. The dependent variables for Columns (1) and (2) are the derivatives of the objective function at the 2015 policy, unconditional on MA enrollment, and are also normalized. The dependent variable in Column (3) is the optimal subsidy schedule of Table 9, in units of thousands of dollars per year. Estimates obtained by OLS. Robust standard errors are in parentheses. Stars indicate p-values: \*\*\* p<0.01, \*\* p<0.05, \* p<0.1.

**Table 13: Comparing the optimal policy to the linear policy rule**

	Optimal Policy	Linear Rule	Percentage Change
Mean CS, unconditional on MA enrollment (\$)	192.65	184.17	-4.40
Total MA share (%)	33.0	31.6	-4.24
Mean CS, conditional on MA enrollment (\$)	583.74	582.82	-0.16
Total consumer surplus (\$ billion)	7.70	7.36	-4.40
Total government expenditures (\$ billion)	391	393	0.51
Number of markets with benchmark increases	331	317	-4.23
<i>Mean unconditional consumer surplus by direction of change relative to 2015 policy</i>			
Markets with benchmark increases (\$)	200.99	223.93	11.4
Markets with benchmark decreases (\$)	167.61	105.66	-37.0
<i>Mean unconditional consumer surplus by demographic group</i>			
White consumers (\$)	191.01	186.42	-2.40
Black consumers (\$)	203.90	192.09	-5.79
Hispanic consumers (\$)	249.86	214.29	-14.2
Low income consumers (\$)	213.74	206.78	-3.26
Medium income consumers (\$)	203.57	196.12	-3.66
High income consumers (\$)	162.80	160.51	-1.41

Notes: This table compares surplus under the optimal policy and the policy predicted by the regression results in Column (3) of Table 12. Consumer surplus is calculated via Equation 8; surplus figures are in dollars per Medicare-beneficiary-year. White, Black, and Hispanic groups are defined by CMS. All statistics are weighted by the MCBS sample weights.

implications if the changes result in a large-scale redistribution of government expenditures and consumer surplus dollars from states with one political alignment to states with an opposing alignment. To explore these issues, we summarize the total consumer surplus and government expenditures by state in Appendix Table C.6. Of the 41 states (plus Washington D.C.) included in the MCBS, 35 receive aggregate increases in consumer surplus; only Arkansas, Florida, Louisiana, Oklahoma, South Dakota, and Wisconsin experience decreases. Other southern states including Alabama, Georgia, North and South Carolina, Texas, and Virginia receive increases. These results suggest the optimal policy does not split along political divisions.

While our approach finds an equilibrium in prices taking product characteristics as given, there may be approximation error in our simulated outcomes coming from errors in our policy functions. To investigate this, we calculate the change in variable profits firms would obtain by deviating from the predicted policy functions for out-of-pocket costs and the adjusted  $\delta$  term by 1%. As we estimate marginal costs by inverting the first-order conditions related to price alone, we do



not expect the first-order conditions for the other product characteristics to hold precisely at the observed 2015 values. To isolate the error introduced by our approximation approach, we calculate the change in profits for deviations from the estimated characteristics at the optimal policy and subtract it from the change in profits for deviations from the observed 2015 characteristics.

The results are reported in Appendix Table C.8. Across all markets, the mean change in profit from a 1% increase in out-of-pocket costs is -0.03%, and the mean change in profit from an increase in the adjusted  $\delta$  term is 0.05%, indicating that our approximation approach does not introduce significant error on average. The Monte Carlo results in Appendix A suggest that any approximation error may vary in part based on the change in the benchmark; those markets with greater changes may have a greater approximation error. The last rows of Appendix Table C.8 split markets into those with changes in the benchmark of more and less than \$1,000. As expected, the 57 markets with changes greater than \$1,000 have slightly more profitable deviations – the mean change in variable profit from a 1% change in adjusted  $\delta$  is 0.20%.

Finally, we quantify the importance of the product characteristic channel in Appendix Table C.9 by calculating the consumer surplus when prices are set to the equilibrium level under the optimal policy but product characteristics are held at observed 2015 levels. On average, the change in the product characteristics contributes roughly 3% to the overall change in consumer surplus, though this rate varies across demographic groups.

### 8.3 Alternative social welfare functions

The results in the previous subsection show the optimal policy creates winners and losers relative to the current policy. We explore a number of other social welfare functions in Table 14 and compare the policies generated by these functions to the optimal policy. Columns (2) and (3) maximize consumer surplus with a penalty assessed on the variance of consumer surplus across individuals. In Column (2), the penalty on variance causes a reduction in benchmarks nearly everywhere in order to fund increases in a few of markets; the total consumer surplus drops from \$5.94 billion under the 2015 policy to \$2.91 billion. Column (3) reduces the penalty on the variance, which results in a policy very similar to the optimal policy. Relative to the optimal policy, total consumer surplus falls 3.63% to \$7.42 billion. Appendix Figure C.4 illustrates the optimal benchmark distribution under this scenario. 83% of counties receive increases, and the interquartile range extends from \$5 to \$763. In percentage terms, the increases are similar – 75% are of less than 10%.

Column (4) seeks to minimize government expenditures. Where the 2015 MA payments are

larger than the cost of TM, this is done by reducing the benchmark. However, there are markets where the 2015 policy results in MA payments that are on average lower than TM costs. Increasing the benchmark results in both intensive and extensive margin changes to MA payments: the government must pay more for consumers who were already enrolled in an MA plan, and must transfer payments from the TM system to the MA system for consumers who switch. In 164 markets, the extensive margin impact is larger than the intensive margin impact, and therefore an increase in the benchmark rate results in a decrease in total government expenditures.<sup>30</sup> As a result, the government can reduce total spending on TM and MA by 0.5%, though at the cost of 19.9% of consumer surplus relative to the 2015 policy.

Column (5) seeks a “Pareto improvement” by minimizing government expenditures subject to the constraint that no benchmark is lowered below its 2015 level. As the benchmark is raised in 164 markets, total consumer surplus increases 10.0% from the 2015 policy to \$6.54 billion. At the same time, government spending is reduced by roughly \$1 billion.

## 9 Conclusion

Seeking to reduce the perceived inefficiency of government-provided goods and services, policy makers in a number of contexts have implemented public-private partnerships in which the government provides subsidies to private firms that are tied to the choices of consumers. The firms are then free to compete with each other – with competition and market forces working to bring down the total cost and increase the benefits of providing the good over time. In many cases, the goods provided by firms have differentiated characteristics which are relevant to consumers. Additionally, these goods may be offered in geographies with consumers who have substantially different preferences. While the subsidy rates are generally set according to measures of government costs, the optimal subsidies conditional on a fixed budget depend on equilibrium interactions between heterogeneous supply and demand conditions.

We provide a framework for calculating the optimal subsidies that takes into account both the supply and demand responses to alternative subsidy rates. We model demand with a discrete-choice system and avoid the curse of dimensionality in product characteristics by using an approximation approach for calculating the supply decisions. We rely on the observation of variation in the key parameters we wish to vary in the counterfactual analysis, and combine policy function estimation

---

<sup>30</sup>In Appendix B we illustrate government expenditures as a function of the benchmark for several markets, including a market which features this behavior.

**Table 14: Surplus, share, and spending under the optimal policy and alternative social welfare functions**

	(1)	(2)	(3)	(4)	(5)
	Optimal Policy	Max 0.99 CS - 0.01 Var	Max 0.999 CS - 0.001 Var	Minimize <i>GovExp</i>	Min. Exp. With Floor
Mean CS, unconditional on MA enrollment (\$)	192.65	72.93	185.60	119.11	163.58
Total MA share (%)	33.0	16.3	33.6	23.3	29.4
Mean CS, conditional on MA enrollment (\$)	583.74	446.06	552.58	510.83	556.67
Total consumer surplus (\$ billion)	7.70	2.91	7.42	4.76	6.54
Total government expenditures (\$ billion)	391	391	391	389	390
Number of markets with benchmark increases	331	133	368	164	164
<i>Mean unconditional consumer surplus by direction of change relative to 2015 policy</i>					
Markets with benchmark increases (\$)	200.99	62.03	176.56	127.64	139.35
Markets with benchmark decreases (\$)	167.61	76.28	227.96	112.92	N/A
<i>Mean unconditional consumer surplus by demographic group</i>					
White consumers (\$)	191.01	71.04	183.33	116.35	160.82
Black consumers (\$)	203.90	89.58	203.81	142.65	180.77
Hispanic consumers (\$)	249.86	108.58	243.59	178.89	273.91
Low income consumers (\$)	213.74	83.47	210.03	134.65	184.05
Medium income consumers (\$)	203.57	76.37	193.71	124.53	171.00
High income consumers (\$)	162.80	59.87	155.23	99.57	137.55

Notes: This table compares surplus under alternative objective functions. Columns (2) and (3) maximize consumer surplus with a penalty on the variance of consumer surplus across individuals. Column (4) minimizes the sum of government expenditures across MA and TM. Column (5) also minimizes the sum of government expenditures, with the constraint that no benchmark can be reduced relative to the 2015 policy. Consumer surplus is calculated via Equation 8; surplus figures are in dollars per Medicare-beneficiary-year. White, Black, and Hispanic groups are defined by CMS. All statistics are weighted by the MCBS sample weights.

with a first-order condition solver for prices.

We apply our framework to the Medicare Advantage program in the United States, through which approximately one-third of U.S. seniors obtain Medicare benefits, and estimate our model using micro-level panel data. We find that the optimal subsidies differ substantially from those currently employed by the government. The current policy generates an average of \$148.65 in consumer surplus per person per year. By maximizing the mean consumer surplus, we find an alternative policy that results in an average of \$192.65 in benefits per person per year. These gains come largely from finding places where it is relatively easy (in the sense of needing fewer government dollars) to move people from TM to MA rather than improving benefits for people already on an MA plan. We show that freely-available market-level observables can be used to approximate the optimal policy rule with a linear rule that reduces consumer surplus by 4.4% and increases government expenditures 0.5% relative to the optimal policy.

Our framework can be adopted to any market in which subsidized firms offer differentiated products. For example, many charter schools offer specialized curricula which may appeal to different sets of parents. With data on family characteristics and choices, the benefits created by these schools and the outcomes of alternative voucher-style policies could be calculated.

## References

- Aizawa, N. and Kim, Y. S. (2018). Advertising and risk selection in health insurance markets. *American Economic Review*, 108(3):828–67.
- Angrist, J. D. and Pischke, J.-S. (2010). The credibility revolution in empirical economics: How better research design is taking the con out of econometrics. *Journal of Economic Perspectives*, 24(2):3–30.
- Bajari, P., Benkard, C. L., and Levin, J. (2007). Estimating dynamic models of imperfect competition. *Econometrica*, 75(5):1331–1370.
- Baum-Snow, N. and Marion, J. (2009). The effects of low income housing tax credit developments on neighborhoods. *Journal of Public Economics*, 93(5):654–666.
- Benkard, C. L., Bodoh-Creed, A., and Lazarev, J. (2018). Simulating the dynamic effects of horizontal mergers: U.s. airlines. *Working Paper*.
- Berry, S. (1994). Estimating discrete-choice models of product differentiation. *The RAND Journal of Economics*, pages 242–262.
- Berry, S., Levinsohn, J., and Pakes, A. (1995). Automobile prices in market equilibrium. *Econometrica*, 63(4):pp. 841–890.
- Bundorf, M. K., Levin, J., and Mahoney, N. (2012). Pricing and welfare in health plan choice. *American Economic Review*, 102(7):3214–48.

- Cabral, M., Geruso, M., and Mahoney, N. (2018). Does privatized medicare benefit patients or producers? evidence from the benefits improvement and protection act. *American Economic Review*.
- CMS Office of the Actuary (2017). Actuarial bid training–2017.
- Curto, V., Einav, L., Levin, J., and Bhattacharya, J. (2018). Can health insurance competition work? evidence from medicare advantage. Working Paper 20818, National Bureau of Economic Research.
- Dalton, C. M., Gowrisankaran, G., and Town, R. (2018). Saliency, myopia, and complex dynamic incentives: Evidence from Medicare Part D. Technical report, National Bureau of Economic Research.
- Daskalakis, C., Goldberg, P., and Papadimitriou, C. (2009). The complexity of computing a nash equilibrium. *SIAM Journal on Computing*, 39(1):195–259.
- Decarolis, F. and Guglielmo, A. (2017). Insurers’ response to selection risk: Evidence from Medicare enrollment reforms. *Journal of Health Economics*, 56:383–396.
- Decarolis, F., Polyakova, M., and Ryan, S. P. (2015). Subsidy design in privately-provided social insurance: Lessons from medicare part d. Working Paper 21298, National Bureau of Economic Research.
- Duggan, M., Starc, A., and Vabson, B. (2016). Who benefits when the government pays more? pass-through in the medicare advantage program. *Journal of Public Economics*, 141:50–67.
- Einav, L., Finkelstein, A., and Tebaldi, P. (2018). Market design in regulated health insurance markets: Risk adjustment vs. subsidies. *MIT Working Paper*.
- Enthoven, A. C. (1978). Consumer-Choice Health plan (second of two parts). A national-health-insurance proposal based on regulated competition in the private sector. *N. Engl. J. Med.*, 298(13):709–720.
- Ericson, K. M. and Starc, A. (2015). Measuring consumer valuation of limited provider networks. *American Economic Review*, 105(5):115–19.
- Fan, Y. (2013). Ownership consolidation and product characteristics: A study of the us daily newspaper market. *American Economic Review*, 103(5):1598–1628.
- Geruso, M. and Layton, T. (2018). Upcoding: Evidence from medicare on squishy risk adjustment. Working Paper 21222, National Bureau of Economic Research.
- Geruso, M. and Layton, T. J. (2017). Selection in health insurance markets and its policy remedies. *Journal of Economic Perspectives*, 31(4):23–50.
- Glazer, J. and McGuire, T. G. (2000). Optimal risk adjustment in markets with adverse selection: An application to managed care. *American Economic Review*, 90(4):1055–1071.
- Goolsbee, A. and Petrin, A. (2004). The consumer gains from direct broadcast satellites and the competition with cable tv. *Econ*, 72(2):351–381.
- Gruber, J. (2017). Delivering public health insurance through private plan choice in the united states. *Journal of Economic Perspectives*, 31(4):3–22.

- Handel, B. R. (2013). Adverse selection and inertia in health insurance markets: When nudging hurts. *American Economic Review*, 103(7):2643–82.
- Hausman, J., Leonard, G., and Zona, J. D. (1994). Competitive analysis with differentiated products. *Annales d'économie et de Statistique*, 34:159–180.
- Hefti, A. (2017). Equilibria in symmetric games: Theory and applications. *Theoretical Economics*, 12(3):979–1002.
- Ho, K. and Lee, R. S. (2018). Equilibrium provider networks: Bargaining and exclusion in health care markets. Working Paper 23742, National Bureau of Economic Research.
- Hoxby, C. M. (2000). Does competition among public schools benefit students and taxpayers? *American Economic Review*, 90(5):1209–1238.
- Jaffe, S. P. and Shepard, M. (2017). Price-linked subsidies and health insurance markups. Working Paper 23104, National Bureau of Economic Research.
- Laffont, J.-J. and Tirole, J. (1993). *A theory of incentives in procurement and regulation*. MIT press.
- Levin, H. M. (2002). A Comprehensive Framework for Evaluating Educational Vouchers. *Educational Evaluation and Policy Analysis*, 24(3):159–174.
- Lustig, J. (2010). Measuring Welfare Losses from Adverse Selection and Imperfect Competition in Privatized Medicare. Working paper, Yale University.
- Maruyama, S. (2011). Socially optimal subsidies for entry: The case of medicare payments to hmos. *International Economic Review*, 52(1):105–129.
- McGuire, T. G., Newhouse, J. P., and Sinaiko, A. D. (2011). An economic history of Medicare part C. *Milbank Quarterly*, 89(2):289–332.
- MedPAC (2017). Status report on the medicare advantage program. In *Report to the Congress: Medicare Payment Policy*, chapter 13, pages 345–379. MedPAC.
- Nevo, A. and Whinston, M. D. (2010). Taking the dogma out of econometrics: Structural modeling and credible inference. *Journal of Economic Perspectives*, 24(2):69–82.
- Newhouse, J. P., Price, M., Hsu, J., McWilliams, J. M., and McGuire, T. G. (2015). How much favorable selection is left in medicare advantage? *American journal of health economics*, 1(1):1–26.
- Newhouse, J. P., Price, M., Huang, J., McWilliams, J. M., and Hsu, J. (2012). Steps to reduce favorable risk selection in medicare advantage largely succeeded, boding well for health insurance exchanges. *Health Affairs*, 31(12):2618–2628. PMID: 23213145.
- Noel, M. D. (2007). Edgeworth price cycles, cost-based pricing, and sticky pricing in retail gasoline markets. *The Review of Economics and Statistics*, 89(2):324–334.
- Nosal, K. (2012). Estimating switching costs for medicare advantage plans. Working paper, University of Arizona.

- Rinnooy Kan, A. and Timmer, G. (1987). Stochastic global optimization methods. part ii: multi level methods. *Mathematical Programming*, 39(1):57–78.
- Rothschild, M. and Stiglitz, J. (1976). Equilibrium in Competitive Insurance Markets: An Essay on the Economics of Imperfect Information\*. *The Quarterly Journal of Economics*, 90(4):629–649.
- Small, K. A. and Rosen, H. S. (1981). Applied welfare economics with discrete choice models. *Econometrica: Journal of the Econometric Society*, pages 105–130.
- Song, Z., Landrum, M. B., and Chernew, M. E. (2013). Competitive bidding in medicare advantage: Effect of benchmark changes on plan bids. *Journal of health economics*, 32(6):1301–1312.
- Tebaldi, P. (2017). Estimating equilibrium in health insurance exchanges: Price competition and subsidy design under the aca. Working paper, University of Chicago.
- Town, R. and Liu, S. (2003). The welfare impact of Medicare HMOs. *Rand J Econ*, 34(4):719–736.

# Appendices

## A Monte Carlo Analysis of Supply Approximations

Our approach approximates the responses of firms to changes in the benchmark instead of solving for the full equilibrium response – in particular, we approximate the change in plan characteristics and then solve for the equilibrium in prices. An obvious question is how well do such approximations work in practice. In this appendix, we run several Monte Carlo experiments to examine this issue.

In these experiments, we simulate market-level data for two periods. We use the results in the first period as the basis for making predictions of the second period market outcomes. We explicitly solve the firm’s problem in the second period, and compare the exact solution to an approximation created using the first period data and the approach we employ in the paper. For simplicity, we specify utility as  $u_{ijmt} = \delta_{jmt} - \alpha p_{jmt}^2 + e_{ijmt}$  where  $e_{ij}$  is an iid Type I Extreme Value error term. We allow price to affect utility in a nonlinear way as it allows for greater concavity in the plans objective function – alternatively we could have allowed for convexity in the cost specification. Plan costs are given by  $c_{jmt} = \exp(.2 + .2\delta_j + \nu_j)$  where  $\nu_j$  is drawn from a  $N(0, .1)$ . In each period, we simulate  $M$  markets where  $M$  is 50, 100 or 200. In each market, the insurers receive a subsidy,  $z_{mt}$ . In the first period, the market-level subsidy is sequentially ordered and ranges from .1 to 1.1 with an interval of .1. In the second period we reverse the order of the subsidies so that the highest subsidy market is now the lowest and vice versa. In the simulations we allow the number of market participants to range from 3 to 7.

In order to forecast the equilibrium with new benchmarks, we follow a procedure that mimics our empirical approach. Specifically, we use the first period equilibrium results to estimate demand and given those results, invert the premium setting first-order condition to recover implied marginal cost,  $\hat{m}c_{jmt}$ . We then regress the implied  $\delta_{jm1}$  on  $\hat{m}c_{jmt}$  and its square to recover the cost function parameters. Importantly, we estimate the relationship between the implied  $\delta_{jm1}$  and the benchmarks  $z_{m1}$  and use the results from this regression to forecast  $\delta_{jm1}$  given the updated subsidies,  $z_{m2}$ . We then calculate the new expected marginal cost and then solve for the new premiums given the subsidies, the updated  $\delta_{jm2}$  and  $c_{jm2}$ . We compare these results to the actual impact of changing the benchmarks where the actual impact is calculated by explicitly solving for premiums and  $\delta_{jm2}$  using the plans’ first-order conditions for both premiums and  $\delta_{jm2}$  given the parameters of the model.



**Table A.1: Monte Carlo Evidence**

Number of Markets	Number of Plans	Mean $Err^{CS}$	Mean Absolute $Err^{CS}$
50	3	.0014	.0094
100	3	.0011	.0076
200	3	.00077	.0037
50	4	.00093	.0051
100	4	.00064	.0025
200	4	.00095	.0051
50	5	.00065	.0027
100	5	.0011	.0060
200	5	.0013	.0080
50	6	.0011	.0050
100	6	.0016	.0091
200	6	.0012	.0064
50	7	.0011	.0055
100	7	.0013	.0063
200	7	.0013	.0070


Notes: This table presents the results of a Monte Carlo exercise which compares our equilibrium approximation approach to actual equilibrium solutions for a simple model in which firms choose a single price and a single product characteristic.

We define the logarithm error as  $Err^{CS} = \text{Log}(CS_{Exact}) - \text{Log}(CS_{approx})$ . Table A.1 presents some of the key statistics from our Monte Carlo experiments. The results displayed in the table indicate that our approximation approach generates estimates of consumer surplus, our key outcome that we need to match, that are very close to an approach using an exact solution. Figure A.1 illustrates this for a run with 7 firms and 200 markets. Red circles indicate the consumer surplus calculated when the firms' problem is solved explicitly, and the blue circles indicate the consumer surplus found using our approximation approach. The Figure shows our approach works well across the range of subsidies, and works particularly well near the middle of the subsidy range.

## B The non-local behavior of surplus and expenditures

The results in Section 8.2 show that the local behavior of the surplus and expenditure functions at the 2015 policy, in the form of the derivatives of these functions with respect to the benchmark, point to the direction of the optimal policy. However, the derivatives alone do not provide sufficient information to calculate the optimal policy. Though the policy function approximations we use are linear, the pricing and share functions are not – indeed, the logit share function has both concave

Figure A.1: Monte Carlo Results for Seven Firms



Notes: This figure illustrates the results of our Monte Carlo exercise with seven firms per market and 200 simulated markets. The horizontal axis is the subsidy from the government and the vertical axis is the equilibrium consumer surplus.

and convex portions – and so we should expect the  $CS$  and  $GovExp$  functions to be non-linear as well. In this Appendix, we explore the non-local behavior of the surplus and expenditure functions through illustrated examples.


Figure B.1 illustrates components of the  $CS_m$  function for Travis County, TX (containing Austin), Cook County, IL (containing Chicago), and Worth County, GA (a rural county near Albany). We chose these counties due to their different sizes and the typical nature of their counterfactual equilibria. The first graph illustrates the share-weighted  $\delta'_j$  as a function of the benchmark. All three counties show increases as the benchmark increases. However, Cook County, in which 26 plans are offered, shows a larger increase than Travis County, which has 13 plans, or Worth County, which has 3 plans. The second graph depicts the share-weighted average OOPC for the 65-69 Good category and shows non-monotonicity as the benchmark increases, illustrating the relative weight of the out-of-pocket costs in the utility function. The third graph shows the share-weighted average price. The price increases slightly in Cook County for some benchmark increases due to substitution. As the benchmark increases, prices hit the zero lower bound.

Figure B.2 illustrates components of  $GovExp_m$  for the same counties. The left-hand graph depicts the total inside share of MA. Cook County, which experiences the largest increase in average plan  $\delta$  and also has the most plans available, sees the highest increases. The right-hand graph shows the share-weighted average bid. Cook County's bids increase nearly 1-for-1 with an increase in the benchmark, whereas the average bid in Travis County increases with a shallower slope, and Worth County's bids remain almost flat despite increasing benchmarks.

Figure B.3 combines these components into the  $CS_m$  and  $GovExp_m$  functions. The first graph shows per-capita consumer surplus. Under the current policy, the three counties receive similar surplus. As the benchmark in each county is increased, the average surplus in Cook County grows faster than the others, eventually overtaking them after an increase of \$1,000. In the prior section, we found that the pricing mechanism was the biggest contributor to gains near the 2015 policy. This graph illustrates that this remains true even at some distance from the 2015 policy; though increases in CS still occur after all plans are offered with zero price, the slope is closer to zero. The second graph illustrates per-capita government expenditures. This graph illustrates the potential gains noted in the previous section: Cook and Travis Counties have a flat or even decreasing level of government expenditures for modest increases in the benchmark rate. These graphs suggest that significant gains are possible in some markets simply by incentivizing switches from TM to MA.


The second graph also illustrates the effect of the MA payment system (Equation 2), which

**Figure B.1: Product characteristics under counterfactual benchmarks, selected counties**




Notes: These graphs illustrate three outputs from our counterfactual simulations: the price-adjusted  $\delta_j$ , OOP costs for a 65-69 year old in Good health, and the product’s premium. These outputs are shown for Travis County, TX (which contains Austin), Cook County, IL (which contains Chicago), and Worth County, GA (which is a rural county near Albany). The horizontal axis is the change in the benchmark relative to the 2015 level. All outputs are averages across plans weighted by the market share of each plan.

**Figure B.2: Average plan bids and MA share under counterfactual benchmarks, selected counties**



Notes: These graphs illustrate two outputs from our counterfactual simulation: the total share of MA (as opposed to TM) and the share-weighted average plan bid. These outputs are shown for Travis County, TX (which contains Austin), Cook County, IL (which contains Chicago), and Worth County, GA (which is a rural county near Albany). The horizontal axis is the change in the benchmark relative to the 2015 level.

**Figure B.3: Per-capita consumer surplus and government expenditures under counterfactual benchmarks, selected counties**



Notes: These graphs illustrate two outputs from our counterfactual simulation: the per-capita consumer surplus and the per-capita government spending. The third graph illustrates the ratio of consumer surplus to government spending. These outputs are shown for Travis County, TX (which contains Austin), Cook County, IL (which contains Chicago), and Worth County, GA (which is a rural county near Albany). The horizontal axis is the change in the benchmark relative to the 2015 level.


rebates a portion of the difference between the bid and the benchmark back to firms. Despite the fact that bids in Worth County stay nearly constant, expenditures increase with the benchmark.

The final graph of Figure B.3 combines the two functions to show the average MA surplus delivered to consumers per dollar spent by the government on the Medicare program. The slope of this line is related to the marginal impact of spending an extra dollar in a particular county through the MA benchmark mechanism, which is the key margin explored by the constrained maximization algorithm of our optimal policy search. Over small increases in the benchmark, Worth County experiences the largest gains in surplus per expenditures. However, Cook County offers the largest possible overall gains of these counties. In other words, the optimal allocation of funds to these counties depends in part on the level of funds available for allocation.


## C Additional tables and figures

Figure C.1: Medicare Advantage Benchmark Distribution, 2015

(a) Benchmarks across counties




(b) Benchmarks across beneficiaries




Note: Includes counties observed within the Medicare Current Beneficiary Survey.

Figure C.2: Medicare Advantage Benchmarks and Penetration by County, 2015



Notes: Data from CMS benchmark and enrollment files. Penetration is defined as the total number of people enrolled in any MA plan divided by the number of people eligible for Medicare benefits.


Figure C.3: County-level estimated MA and TM costs



Notes: Each dot in this figure represents a county in 2015. MA costs are implied by the firms' first order conditions for optimal pricing and weighted by market share. TM costs come from CMS data on realized expenditures and county-level average risk; both MA and TM costs are normalized to a risk 1.0 enrollee.



**Figure C.4: Optimized benchmarks by county under variance-penalized objective function**



Notes: These graphs illustrate the optimal policy described in Column (2) of Table 14: the weight on consumer surplus is 0.999 and the weight on variance is 0.001. The left-hand graph shows the distribution of benchmarks under the variance-penalized policy and the right-hand graph illustrates the distribution of the change in benchmarks from the 2015 policy to the variance-penalized policy.

**Table C.1: MA plan summary statistics**

Variable	Mean	
	Unweighted	Enrollment-weighted
Level of observation	Plan-County-Year	Plan-Year
Annual premium (\$)	509	395
Annual Part B premium reduction (\$)	30.29	22.63
Deductible (\$)	94.03	50.80
Out-of-pocket limit (\$)	3,846	3,944
Star rating	2.40	3.31
Supplemental coverage indicators		
Prescription drug	.764	.954
Dental	.608	.659
Vision	.890	.940
Plan type indicators		
HMO	.450	.791
PPO	.276	.156
PFFS	.273	.053
Copays		
Primary care (\$)	11.31	9.00
Specialist (\$)	27.81	25.55
Hospital stay (\$)	237	207
Coinsurance		
Primary care (%)	.476	.132
Specialist (%)	.358	.122
Hospital stay (%)	.059	.050
Selected CMS-estimated out-of-pocket costs		
65-69 year-old, excellent health (\$)	1,384	1,278
75-79 year-old, good health (\$)	2,450	2,123
85+ year-old, poor health (\$)	4,099	3,581
Enrollment	672	20,688
Number of counties covered	14.6	8.47
Observation	50,593	10,751

Notes: This table reports summary statistics for the plans in county-year markets in which we observe micro-data through the Medicare Advantage Beneficiary Survey (MCBS). The first column reports raw means across all plan-county-year observations. Many plans are available across multiple counties, and so the second column collapses the data to the plan-year level and weights the resulting observations by total enrollment. All prices are in 2015 dollars. The Star rating is calculated by CMS and ranges from zero to five. We obtain 30 out-of-pocket cost estimates for each plan, though report only three here for brevity.

**Table C.2: Correlations between year-over-year changes in the benchmark and changes in product characteristics**

Variable	Correlation
Premium	-.092
Part B premium reduction	.049
Deductible	.080
Out-of-pocket limit	-.146
Star rating	.145
Copays	
Primary care (\$)	-.010
Specialist (\$)	-.113
Hospital stay (\$)	-.025
Coinsurance	
Primary care (%)	-.091
Specialist (%)	-.009
Hospital stay (%)	.003
Selected CMS-estimated out-of-pocket costs	
65-69 year-old, excellent	-.058
75-79 year-old, good health	-.098
85+ year-old, poor health	-.042
Obs.	27,710

Notes: An observation in this table is a plan-county-year which has a matching plan in the previous year. The correlations reported in this table are between the change in the county-level benchmark and the change in the stated product characteristic. Some observations are excluded due to changes in the MCBS coverage at the county level from year-to-year.

**Table C.3: Switching costs in dollars by switch type and income group**

Switch type	Income group		
	Low	Medium	High
Medicare-to-MA	\$877	918	894
Between-Insurers	510	534	521
Within-Insurer	167	177	176

Notes: We transform our switching cost parameters into dollars by dividing them by the coefficient on price. To form the statistics reported here, we calculate the effective switching cost for each person based on their health status and income group, and then take the mean by switch type and income group. Observations are weighted by MCBS sampling weights.

**Table C.4: Out-of-pocket cost policy function parameter estimates**

Demographic Cat.	Benchmark	Plan Rank	Leading Insurer	# Plans	$R^2$
Ages 0-64					
Excellent	-.050 (.003)	.113 (.002)	-.071 (.007)	-.004 (.000)	.279
Very good	-.018 (.004)	.142 (.003)	-.106 (.010)	-.008 (.000)	.231
Good	-.055 (.005)	.173 (.003)	-.140 (.013)	-.011 (.000)	.215
Fair	-.073 (.007)	.244 (.005)	-.195 (.018)	-.016 (.000)	.210
Poor	-.093 (.010)	.336 (.007)	-.268 (.025)	-.022 (.001)	.211
Ages 65-69					
Excellent	-.019 (.002)	.071 (.002)	-.062 (.006)	-.006 (.000)	.286
Very good	-.017 (.003)	.098 (.002)	-.083 (.008)	-.008 (.000)	.256
Good	-.063 (.005)	.145 (.003)	-.121 (.011)	-.010 (.000)	.230
Fair	-.087 (.007)	.237 (.005)	-.185 (.018)	-.014 (.000)	.222
Poor	-.162 (.010)	.341 (.006)	-.226 (.024)	-.012 (.001)	.245
Ages 70-74					
Excellent	-.028 (.002)	.079 (.002)	-.066 (.006)	-.006 (.000)	.285
Very good	-.031 (.003)	.104 (.002)	-.085 (.008)	-.007 (.000)	.253
Good	-.059 (.005)	.148 (.003)	-.126 (.011)	-.010 (.000)	.240
Fair	-.114 (.007)	.239 (.005)	-.181 (.018)	-.012 (.000)	.226
Poor	-.209 (.010)	.328 (.006)	-.207 (.024)	-.010 (.001)	.253
Ages 75-79					
Excellent	-.032 (.002)	.083 (.002)	-.056 (.006)	-.004 (.000)	.294
Very good	-.037 (.003)	.109 (.002)	-.085 (.008)	-.007 (.000)	.258
Good	-.060 (.005)	.156 (.003)	-.123 (.011)	-.009 (.000)	.240
Fair	-.091 (.007)	.236 (.005)	-.179 (.017)	-.013 (.000)	.228
Poor	-.088 (.010)	.314 (.006)	-.267 (.024)	-.023 (.001)	.240
Ages 80-84					
Excellent	-.039 (.002)	.085 (.002)	-.055 (.006)	-.004 (.000)	.300
Very good	-.054 (.003)	.111 (.002)	-.082 (.008)	-.006 (.000)	.270
Good	-.071 (.005)	.158 (.003)	-.130 (.011)	-.009 (.000)	.245
Fair	-.101 (.007)	.240 (.005)	-.174 (.017)	-.012 (.000)	.239
Poor	-.102 (.010)	.319 (.006)	-.259 (.024)	-.021 (.001)	.250
Ages 85+					
Excellent	-.054 (.003)	.105 (.002)	-.066 (.007)	-.002 (.000)	.312
Very good	-.062 (.003)	.122 (.002)	-.085 (.008)	-.004 (.000)	.285
Good	-.076 (.005)	.164 (.003)	-.134 (.012)	-.008 (.000)	.249
Fair	-.101 (.007)	.240 (.005)	-.181 (.017)	-.013 (.000)	.241
Poor	-.083 (.010)	.307 (.006)	-.281 (.024)	-.022 (.001)	.248

Notes: Each row of this table reports the OLS coefficients for a different regression. The dependent variable for each regression is the out-of-pocket cost estimate for a particular age-health demographic group. The columns are the independent variables as defined in Table 7. Each regression has 50,593 plan-market observations. Robust standard errors are in parentheses.

**Table C.5: Mean county characteristics by benchmark quartile, 2015 policy versus optimal policy**

<b>2015 policy</b>	<b>0-25th</b>	<b>26-50th</b>	<b>51-75th</b>	<b>76-100th</b>
Risk-adj. TM costs per capita	\$9,128	9,373	9,908	10,726
Average risk score	.981	.974	.989	1.03
Beneficiaries	31,199	34,711	59,852	110,096
Median household income	53,405	50,899	58,534	62,810
Percent in deep poverty, 65+	2.71	2.49	2.59	2.78
Unemployment rate	5.69	5.64	5.38	5.38
Population density (per mi <sup>2</sup> )	481	344	649	3,051
Resources per 10,000 people				
MDs	18.5	20.1	21.1	27.2
Medicare hospitals	.027	.023	.039	.034
Skilled nursing facilities	.600	.689	.673	.456
Hospice facilities	.151	.144	.116	.113
Medicare hospital readmission rate	17.0	17.2	17.6	18.3
Preventable hospital admission rate	51.2	55.8	53.4	52.7
2015 benchmark	8,610	8,916	9,183	9,962
Number of MA plans	12.2	12.8	14.2	17.9
Number of MA firms	6.49	6.91	7.7	9.0
Obs.	112	111	111	111
<b>Optimal policy</b>	<b>0-25th</b>	<b>26-50th</b>	<b>51-75th</b>	<b>76-100th</b>
Risk-adj. TM costs per capita	\$8,822	9,433	9,865	11,019
Average risk score	.989	.992	.983	1.01
Beneficiaries	31,323	51,297	48,772	104,465
Median household income	49,827	52,693	55,992	67,169
Percent in deep poverty, 65+	2.80	2.65	2.49	2.63
Unemployment rate	5.84	5.58	5.29	5.37
Population density (per mi <sup>2</sup> )	331	585	799	2,813
Resources per 10,000 people				
MDs	16.3	20.0	22.0	28.6
Medicare hospitals	.027	.031	.032	.033
Skilled nursing facilities	.577	.599	.649	.593
Hospice facilities	.154	.117	.143	.111
Medicare hospital readmission rate	16.9	17.2	17.7	18.2
Preventable hospital admission rate	51.6	52.2	57.5	51.8
Optimal benchmark	8,555	9,166	9,624	10,650
Number of MA plans	13.0	14.8	13.5	15.9
Number of MA firms	7.06	8.13	7.00	7.96
Obs.	112	111	111	111

Notes: This table reports county characteristics from CMS, Census, and Area Health Resource File data across benchmark quartiles. The top panel defines benchmark quartiles according to the 2015 policy and sorts counties according to their 2015 benchmark. The bottom panel defines quartiles according to the optimal policy and sorts counties accordingly.

**Table C.6: State-level changes in surplus and expenditures from 2015 policy to optimal benchmark schedule**

State	# counties	Sum(weight) (000,000s)	Consumer surplus (\$ M)			Government expenditures (\$ M)		
			2015	Optimal	% $\Delta$	2015	Optimal	% $\Delta$
Alabama	14	14.63	130.5	166.6	27.6	13,063	13,088	0.20
Arizona	5	8.36	147.1	148.1	0.7	7,111	7,112	0.01
Arkansas	4	4.36	62.0	61.2	-1.3	3,546	3,544	-0.04
California	18	31.48	699.8	916.7	31.0	34,684	34,832	0.43
Colorado	8	3.95	118.1	150.6	27.5	3,508	3,531	0.64
Connecticut	6	6.34	115.0	199.9	73.7	6,663	6,700	0.56
Dist. of Columbia	1	0.92	1.0	2.7	163.8	1,077	1,078	0.05
Florida	22	29.73	675.5	564.8	-16.4	31,790	31,627	-0.51
Georgia	21	11.12	89.6	97.3	8.5	10,087	10,071	-0.16
Illinois	18	12.46	52.1	125.0	139.7	12,691	12,688	-0.03
Indiana	3	0.65	5.0	9.7	93.7	636	640	0.63
Iowa	4	2.74	10.8	17.4	61.3	2,166	2,164	-0.09
Kansas	3	3.59	21.1	37.1	76.2	3,156	3,161	0.19
Kentucky	8	7.34	60.3	84.9	40.7	6,799	6,808	0.14
Louisiana	5	4.44	159.4	61.0	-61.7	4,758	4,582	-3.71
Maryland	8	6.01	4.6	28.7	526.6	6,571	6,553	-0.27
Massachusetts	8	5.71	43.8	153.9	251.1	6,439	6,462	0.36
Michigan	32	21.63	233.6	465.6	99.3	22,325	22,315	-0.04
Minnesota	13	9.80	66.9	131.0	95.9	8,961	8,991	0.33
Missouri	15	8.27	94.2	106.6	13.2	7,696	7,707	0.15
Nebraska	3	2.45	13.7	41.1	200.8	2,235	2,210	-1.12
Nevada	3	4.70	115.3	115.4	0.1	4,822	4,823	0.01
New Hampshire	1	0.03	0.1	0.3	200.1	27	27	0.16
New Jersey	16	15.29	90.1	312.2	246.5	17,495	17,487	-0.05
New Mexico	5	10.60	252.2	259.5	2.9	7,495	7,495	0.00
New York	28	27.57	779.5	931.3	19.5	29,257	29,248	-0.03
North Carolina	25	18.68	290.1	301.2	3.8	17,739	17,690	-0.28
Ohio	30	18.31	228.4	473.0	107.1	17,764	17,928	0.92
Oklahoma	2	4.09	8.6	3.0	-65.2	3,592	3,581	-0.31
Pennsylvania	25	18.43	370.3	623.8	68.5	18,287	18,444	0.86
Rhode Island	1	0.03	0.5	0.5	1.4	30	30	0.02
South Carolina	7	3.67	17.2	28.6	66.4	3,422	3,426	0.12
South Dakota	14	8.26	91.8	91.3	-0.5	7,247	7,246	-0.01
Texas	33	30.77	312.6	399.3	27.7	31,891	31,896	0.02
Utah	1	0.05	0.6	0.6	0.9	46	46	0.01
Vermont	1	0.01	0.0	0.1	241.1	6	6	-0.18
Virginia	9	7.03	42.3	55.7	31.7	6,390	6,400	0.15
Washington	8	16.55	207.5	307.8	48.3	13,470	13,513	0.32
West Virginia	4	3.74	33.6	47.3	40.6	3,048	3,032	-0.52
Wisconsin	11	14.33	290.3	172.5	-40.6	12,360	12,170	-1.54
Wyoming	2	1.47	5.6	5.8	3.5	1,167	1,167	-0.01
Total	445	400	5,940	7,699	29.6	391,517	391,519	0

Notes: This table presents state-level summaries of the total consumer surplus and government expenditures at the 2015 policy and our calculated optimal policy. The MCBS uses a sample of counties and weights observations to be nationally representative; the first column reports the number of counties included in the MCBS in each state, and the second column reports the total MCBS sample weight in the state. Consumer surplus is calculated via Equation 8. Government expenditures include expenditures on TM and MA and are calculated via Equation 16. All surplus and expenditure numbers reported here are calculated using MCBS sample weights.

**Table C.7: Market shares and total variable profits for selected firms under 2015 policy and alternative policies**

	(1)	(2)	(3)	(4)	(5)	(6)	(7)
	2015	Optimal	Linear	0.99 CS	0.999 CS	Minimize	Min exp.
	policy	policy	rule	- 0.01 Var	- 0.001 Var	<i>GovExp</i>	with floor
<i>Aetna</i>							
Share of Medicare recipients (%)	.734	1.36	1.34	.609	1.38	.950	1.05
Share of MA enrollees (%)	2.75	4.11	4.26	3.72	4.10	4.07	3.57
Total variable profits (\$ billion)	.104	.233	.255	.276	.242	.144	.159
<i>BlueCross BlueShield (see notes)</i>							
Share of Medicare recipients (%)	3.46	5.32	5.20	2.32	5.49	3.40	4.21
Share of MA enrollees (%)	12.9	16.1	16.5	14.2	16.4	14.6	14.3
Total variable profits (\$ billion)	.558	1.03	1.07	.365	1.04	.579	.719
<i>Humana</i>							
Share of Medicare recipients (%)	5.78	7.20	6.66	3.74	8.16	4.66	6.37
Share of MA enrollees (%)	21.6	21.8	21.2	22.9	24.3	20.0	21.7
Total variable profits (\$ billion)	1.00	1.31	1.29	.601	1.55	.769	1.12
<i>Kaiser Permanente</i>							
Share of Medicare recipients (%)	1.43	1.80	1.73	.759	1.68	1.43	1.50
Share of MA enrollees (%)	5.36	5.46	5.50	4.64	5.01	6.15	5.10
Total variable profits (\$ billion)	.295	.448	.528	.134	.396	.306	.321
<i>UnitedHealth Group</i>							
Share of Medicare recipients (%)	4.63	4.8	4.57	2.78	4.74	3.96	4.77
Share of MA enrollees (%)	17.3	14.5	14.5	17.0	14.1	17.0	16.2
Total variable profits (\$ billion)	.860	.968	1.08	.477	.964	.744	.928
<i>All Others</i>							
Share of Medicare recipients (%)	10.7	12.5	12.0	6.14	12.1	8.92	11.5
Share of MA enrollees (%)	40.1	38.0	38.0	37.6	36.1	38.2	39.1
Total variable profits (\$ billion)	1.93	2.41	2.59	1.07	2.31	1.55	2.11
<i>Total</i>							
Share of Medicare recipients (%)	26.7	33.0	31.5	16.3	33.6	23.3	29.4
Total variable profits (\$ billion)	4.75	6.40	6.85	2.93	6.50	4.1	5.36

Notes: This table compares firm shares and total variable profits under the 2015 policy to each of the alternative policies described in Sections 8.2 and 8.3. Variable profits are computed via Equation 10 using equilibrium prices and estimated marginal costs adjusted for changes in product characteristics under alternative policies. The entries for BlueCross BlueShield include all members of the Blue Cross Blue Shield Association. All statistics are weighted by the MCBS sample weights.

**Table C.8: The profitability of a 1% deviation from predicted product characteristics at the optimal policy relative to the 2015 policy**

<i>An 1% increase in the characteristic at the optimal policy...</i>			
		Out-of-pocket costs	$\delta'$
<i>...leads to a X% change in variable profit relative to the same deviation at the 2015 policy.</i>	<i>All markets</i>		
	Mean	-.029	.048
	25th Percentile	-.009	-.008
	Median	-.000	.000
	75th Percentile	.001	.023
	<i>334 markets with increases</i>		
	Mean	-.044	.067
	25th Percentile	-.016	-.020
	Median	-.001	.000
	75th Percentile	.000	.030
	<i>111 markets with decreases</i>		
	Mean	.020	-.012
	25th Percentile	.000	-.000
	Median	.001	.001
	75th Percentile	.002	.009
	<i>57 markets with changes greater than \$1,000</i>		
	Mean	-.123	.196
	25th Percentile	-.156	-.190
	Median	-.018	-.003
	75th Percentile	.000	.349
<i>388 markets with changes less than \$1,000</i>			
Mean	-.018	.032	
25th Percentile	-.006	-.004	
Median	-.000	.000	
75th Percentile	.000	.019	

Notes: This table examines the accuracy of the equilibrium approximation approach described in Section 7.1. For each plan, we calculate the percentage change in the variable profit earned by the firm that offers the plan in response to an increase of 1% in all of the expected out-of-pocket costs or the  $\delta'$  as defined in Equation 17. We update marginal costs per the discussion in Section 7.1 and hold prices and all other product characteristics fixed for all plans in the market. To isolate the effect of our approximation approach, we calculate this difference both at the optimal policy and at the 2015 policy, and subtract the two.



**Table C.9: The contribution of changes in product characteristics to consumer surplus at the optimal policy**

	2015 Policy	Optimal Policy	Fixed Characteristics	Percentage Contribution
Mean CS, uncond. on MA (\$)	148.65	192.65	191.35	2.95
Total MA share (%)	26.7	33.0	32.8	3.17
Mean CS, cond. on MA (\$)	556.02	583.74	583.38	1.28
Total consumer surplus (\$ billion)	5.94	7.70	7.64	2.95
<i>Mean unconditional consumer surplus by direction of benchmark change</i>				
334 markets with benchmark increases (\$)	124.09	200.99	199.07	2.50
111 markets with benchmark decreases (\$)	222.40	167.61	168.17	1.02
<i>Mean unconditional consumer surplus by demographic group</i>				
White consumers (\$)	145.67	191.01	189.67	2.96
Black consumers (\$)	167.90	203.90	202.96	2.61
Hispanic consumers (\$)	262.13	249.86	249.43	3.50
Low income consumers (\$)	166.59	213.74	212.37	2.91
Medium income consumers (\$)	155.37	203.57	202.19	2.86
High income consumers (\$)	125.64	162.80	161.64	3.12

Notes: This table decomposes the change in consumer surplus from the 2015 policy to the optimal policy by isolating the effect of changes in product characteristics. The first column reports data for the 2015 policy and the second column reports the results of maximizing consumer surplus per Equation 13. The third column calculates consumer surplus using the prices under the optimal policy, but with the product characteristics from the 2015 data. The fourth column calculates the contribution of the product characteristics to the overall change in consumer surplus from the 2015 policy to the optimal policy. Consumer surplus is calculated via Equation 8; surplus figures are in dollars per Medicare-beneficiary-year. White, Black, and Hispanic groups are defined by CMS. All statistics are weighted by the MCBS sample weights.